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1.  ZUSAMMENFASSUNG 
Für die Regulation einer vollständigen und adäquaten Immunantwort ist eine 
Kostimulation durch die Bindung des Oberflächenrezeptors CD40 an seinen ebenfalls auf 
der Zelloberfläche lokalisierten Liganden CD154 (CD40L) unabdingbar. Aus 
Untersuchungen an Mäusen und Menschen gibt es jedoch auch überzeugende Belege für 
eine Beteiligung dieses kostimulatorischen Rezeptor-Ligandenpaars  an der Entwicklung 
und dem Fortschreiten chronischer Entzündungen. In ruhenden Endothelzellen fördert die 
durch CD40-CD40L-Interaktion ausgelöste proinflammatorische Reaktion einen Wechsel 
zu einer prothrombotischen und prokoagulierenden Zelloberfläche.  Dieser Prozess geht 
der Atherosklerose voraus und ist an der Ätiologie von kardiovaskulären und 
rheumatischen Erkrankungen beteiligt. 
Ein funktioneller Einzelnukleotidpolymorphismus (single nucleotide polymorphism, 
SNP) in der Kozak-Konsensussequenz des CD40-Gens (-1C>T, rs1883832) ist mit 
Autoimmun- und immun-entzündlichen Erkrankungen assoziiert, indem er die Effizienz 
der Proteintanslation beeinflusst. Basierend auf diesem Kontext haben wir die Hypothese 
aufgestellt, dass dieser SNP das Risiko einer koronaren Herzkrankheit (KHK) in der 
kaukasischen Bevölkerung Baden-Württembergs durch Beeinflussung der endothelialen 
CD40-Expression und -Signaltransduktion erhöhen könnte. 
Um diese Hypothese zu testen, wurde die Verteilung der -1C/T CD40-Variante in einer 
krankenhausbasierten Fall-Kontroll-Studie von Patienten mit KHK untersucht. Die 
Ergebnisse zeigten ein mit dem C-Allel assoziiertes erhöhtes Risiko für KHK (Odds 
Ratio = 1,43; 95% Konfidenzintervall: 1,13-1,86). Die Genotyp-Phänotyp-Analyse ergab, 
dass klonal expandierte Endothelzellen von Trägern mit dem -1CC- gegenüber denen mit 
dem -1TT-Genotyp eine signifikant höhere CD40-Protein-Expression in Verbindung mit 
einem gesteigerten proinflammatorischen Phänotyp zeigen. Zusätzlich wurde bei -1CC- 
im Vergleich zu -1TT-Trägern ein erhöhtes Niveau an zirkulierendem löslichem CD40-
Protein beobachtet. Diese Ergebnisse legen nahe, dass der -1C/T SNP des CD40-Gens 
durch verstärkte Endothelzellenaktivierung eine erhöhte Anfälligkeit für KHK induzieren 
kann. Schließlich war das C-Allel auch bei Patienten mit Psoriasis-Arthritis verglichen 
mit nicht erkrankten Kontrollpersonen signifikant überrepräsentiert, was auf eine 
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generelle Rolle dieses Einzelbasenaustauschs beim Fortschreiten chronischer 
Entzündungserkrankungen hinweist. 
Insgesamt liefern diese Studie neue Belege, die nahelegen, dass das C-Allel des -1C/T 
SNP des CD40-Gens die Anfälligkeit für KHK erhöhen kann, indem es Endothelzellen 
durch eine gesteigerte CD40-Proteinexpression und -Signaltransduktion einen 
proinflammatorischen Phänotyp verleiht und somit eine überschießendezelluläre 
Immunantwort verstärken kann. 
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       1. SUMMARY 
The binding of the co-stimulatory receptor CD40 to its ligand CD154 (CD40L) is 
imperative for orchestrating a complete and adequate immune response. However, there 
is also compelling evidence from mice and human studies to indicate an involvement of 
this co-stimulatory receptor-ligand dyad in the development and progression of chronic 
inflammation. In endothelial cells, the proinflammatory response triggered by CD40-
CD40L interactions facilitates a shift from a quiescent to a prothrombotic and 
procoagulant state; a process which precedes atherosclerosis and is implicated in the 
etiology of cardiovascular and rheumatic diseases.  
A functional single nucleotide polymorphism (SNP) in the Kozak consensus sequence of 
the CD40 gene (-1C>T, rs1883832) is associated with autoimmune and immune-
inflammatory diseases by altering the efficiency of protein translation. Based on this 
context, we hypothesized that this SNP could enhance the risk of coronary heart disease 
(CHD) in the Caucasian population of Baden-Württemberg via influencing endothelial 
CD40 expression and signaling. 
To test this hypothesis, distribution of the -1C/T SNP of the CD40 gene was examined in 
a hospital-based case-control study of CHD. The findings showed an increased risk of 
CHD associated with the C allele (odds ratio = 1.43; 95% confidence interval: 1.13-1.86). 
Genotype-phenotype analysis revealed that endothelial cells from carriers with the -1CC 
versus -1TT genotype exhibited significantly higher CD40 protein expression, along with 
an enhanced proinflammatory phenotype. Additionally, higher circulating soluble CD40 
protein was observed in -1CC compared with -1TT carriers. These results indicate that 
the -1C/T SNP of the CD40 gene may induce susceptibility to CHD via enhanced 
endothelial cell activation. Lastly, the C allele was also significantly over-represented in 
patients with psoriatic arthritis compared to non-diseased controls, indicating a more 
general role for this SNP in driving chronic inflammation. 
Collectively, this study provides novel evidence suggesting that the C allele of -1C/T 
SNP of the CD40 gene may increase susceptibility to CHD by imparting a 
proinflammatory phenotype to endothelial cells through enhanced CD40 protein 
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expression and signaling and therefore augmenting an already exaggerated cellular 
immune response.  
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2 INTRODUCTION 
2.1 Overview of the immune system 
The vertebrate immune system has evolved into two distinct but complementary parts: an 
innate component which forms the first line of defense against invading pathogens, and a 
highly adaptive immune response, which is limited to higher animals. The innate system 
is evolutionarily conserved even in simple life forms and is composed of physical, 
chemical and biological barriers (Delves and Roitt, 2003). Its cellular components 
include leukocytes, phagocytes, bioactive molecules like the cytokines and the 
complement proteins. A central part of this system is the recognition of conserved motifs 
known as pathogen associated molecular patterns (PAMP) present on invading cells by 
the pattern recognition receptors encoded in the germline and displayed on antigen 
presenting cells (APCs).  
The major cellular effectors of the adaptive immune response are the B and T 
lymphocytes which express B cell receptors (BCR) and T cell receptors (TCRs). By the 
process of VDJ (variable, diversity and joining genes) recombination the receptors 
undergo somatic re-arrangement and clonal expression, facilitating the recognition of a 
diverse range of antigens and altered non-self cells such as cancer cells (Schatz and 
Yanhong, 2011). T cells are activated following interaction with antigenic peptide 
fragments presented by major histocompatibility complexes (MHC) on cell surfaces. The 
CD8+ T cells recognize MHC class I presented on most nucleated cells, while CD4+ T 
cells bind to MHC class II complexes on APCs. Consequently, the cells differentiate into 
cytotoxic T cells (CD8+) and T helper cells (CD4+). B cells are stimulated upon 
recognition and interaction with antigens, which they internalize and present on MHC 
class II to type 2 T helper (Th2) cells. This process drives B cell proliferation into 
memory cells or antibody secreting plasma cells, and is known as T cell-dependent B cell 
activation.  
One of the focal points of the immune-inflammatory responses is the CD40-CD40 ligand 
(CD40L) interaction. The CD40 receptor and its cognate ligand form a co-stimulatory 
pathway which is activated when CD40 expressed on B cells interacts with CD40L on the 
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Th2 cells. These interactions play a critical role in autoimmune diseases, signifying their 
importance in the immune system. They induce B cell proliferation, antibody secretion 
and immunoglobulin switching through T cell-dependent B cell activation (Noelle et al., 
1992; Lane et al., 1992 and Kawabe et al., 1994). The CD40-CD40L pathway in 
conjunction with the CD28-CD80/86 pathway is also crucial for the activation of T cells 
and antigen presenting cells (APCs). Therefore, it is also implicated in the process of 
allograft rejection which is primarily a T-helper (Th) 1 response whereby Th1 cells 
interact with resident macrophages acting as APCs (reviewed by Harlan et al., 1999). 
Additionally, during inflammatory conditions CD40L primarily expressed on activated T 
helper cells, self-induced on endothelial cells, or shed from platelets activates endothelial 
cells. This results in the expression of adhesion molecules and release of chemokines 
thereby facilitating the recruitment and activation of circulating monocytes and 
contributing to the maintenance of a chronic immune response (Hollenbaugh et al., 1995; 
Karmann et al., 1995; Wagner et al., 2004). 
2.2 CD40/CD40L system 
2.2.1 Structure  
CD40 is a type 1 transmembrane glycoprotein receptor of the tumour necrosis factor 
receptor superfamily (TNFR). The human CD40 gene is composed of 9 exons and it is 
located at chromosome 20 (q12-q13.2). It contains 277 amino acids (aa) with a 193 aa 
extracellular domain, a 22 aa transmembrane domain, and a 62 aa intracellular domain. In 
a manner similar to all TNFR family members, the extracellular domain contains several 
cysteine-rich regions which are critical for its function and are stabilized by disulfide 
bridges (Stamenkovic et al., 1989; Van Kooten and Banchereau, 2000).  
CD40 signals through its natural ligand known as CD40L (CD154) which is a 5 exon, 
type II, 39 kDa, transmembrane protein mapped to chromosome X (q26.3-q27.1). Its 
extracellular structure consists of two β-sheets sandwiching an α-helix loop that allows 
receptor trimerization, which is typical for tumour necrosis factor (TNF) ligand family 
members (Karpusas et al., 1995). However, proteolytic cleavage can give rise to 
biologically active soluble forms known as sCD40L (Ludewig et al., 1996; Graf et al., 
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1995).While the classical receptor for CD40L is CD40, it can also signal though other 
receptors, namely Mac-1 and α5β1 integrin (Zirlik et al., 2007).  
2.2.2 Expression pattern and induction of the CD40-CD40L dyad  
CD40 was initially characterized on B lymphocytes as a protein essential for all steps of 
B cell development, differentiation and maturation while CD40L was identified on CD4+ 
T cells (Armitage et al., 1992; Koho et al., 1984; Paulie et al., 1984). The importance of 
CD40-CD40L interactions in T cell-dependent-B cell responses was underscored by the 
discovery of point mutations in the CD40L gene in patients with the hyper-IgM 
syndrome (HIGM). This condition develops due to defective switching of the IgM 
antibodies to the IgG, IgE or IgA classes resulting in IgM accumulation. It is 
accompanied by reduced B cell proliferation, a restricted immune response, and increased 
susceptibility to opportunistic as well as viral infections. In experimental mouse models 
with inactivated CD40 or CD40L genes, a similarly defective immune response can be 
observed (Allen et al., 1993; Callard et al., 1993). 
Further studies revealed that CD40-CD40L dyad expression is not restricted to the 
humoral immune system. CD40 is also expressed on other hematopoietic cells including 
monocytes, macrophages, platelets and dendritic cells, non-lymphoid cells like mast cells 
and eosinophils, as well as non-hematopoietic cells such as endothelial cells, epithelial 
cells and vascular smooth muscle cells. CD40L is mainly expressed by B and T cells and 
it is shed from activated platelets. However, under proinflammatory conditions its 
expression can also be induced on other cells including monocytes, mast cells and 
endothelial cells (reviewed by Banchereau et al., 1994 and Schonbeck and Libby, 2001). 
CD40-CD40L interactions are integral in the Th1 immune response since they provide a 
co-stimulation signal which is imperative for T cell differentiation and proliferation, and 
its absence can result in T-cell anergy and depletion (Grewal and Flavell, 1998). The 
expression of CD40L on T cells enables their interaction with the CD40 receptor 
expressed by APCs like monocytes, macrophages and dendritic cells, leading to the 
expression of proinflammatory cytokines and adhesion molecules which facilitates 
atherogenesis. At the same time these bi-directional interactions prime the APCs for 
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activation of CD8+ T cells. In an atherosclerotic context, CD40-CD40L interactions on 
macrophages have particular pathophysiological relevance since they lead to macrophage 
activation which is followed by the release of matric metalloproteinases which induce 
plaque instability via digestion of extracellular collagen matrix  (Lievens et al., 2009; 
Robertson and Hannson; Thim et al., 2008). 
       2.2.3 CD40 signal transduction 
The CD40 signal cascade has been well-studied in B lymphocytes and dendritic cells 
since it plays a crucial role in B cell proliferation and dendritic cell activation. Due to a 
lack of intrinsic signaling activity in CD40, signal propagation occurs largely in 
conjunction with a family of structurally homologous adaptor proteins called tumour 
necrosis factor receptor associated factors (TRAF). Currently there are six known TRAFs 
while the CD40 cytoplasmic domain has simultaneous binding capacity for two 
(Schonbeck and Libby, 2000 and 2001).  
The detectable downstream events of CD40 signal transduction include activation of 
protein tyrosine kinases (PTK), phosphoinositide-3-kinase (PI3-K) and the serine-
threonine kinases, like the mitogen activated protein kinases (MAPK) and stress activated 
protein kinase (SAPK) (Bishop et al., 2007). In addition, the CD40 cytoplasmic tail can 
also associate with the Janus family kinase 3 (Jak 3) resulting in the activation of signal 
transducers and activators of transcription (STAT1). One of the best characterized 
pathways involved in CD40 activation is the prototypical proinflammatory nuclear factor-
κB (NF-kB) pathway, which has a key role in inducing expression of proinflammatory 
cytokines, chemokines and adhesion molecules (Karmann et al., 1995; Saemann et al., 
2002; Saemann et al., 2003). Overall the CD40-CD40L signal cascade is complex and 
can involve multiple pathways depending on the cell type where activation occurs, the 
adaptor molecules that are recruited, and the endocytic pathway involved after receptor 
internalization.  
      2.2.4 Post-transcriptional and post-translational regulation of CD40 
CD40 expression is cytokine inducible and is markedly increased after exposure to a 
combination of tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) which 
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synergistically induce de novo synthesis of CD40. This process is dependent on NF-kB, 
STAT1 and interferon regulatory factor 1 (Wagner et al., 2002). Additionally, CD40 is 
also regulated by gene splicing at the post-transcriptional level and at the post-
translational level.  
CD40 post-transcriptional regulation has not been widely studied. However, the presence 
of evolutionarily conserved isoforms has been detected in mice and humans. In addition 
to isoform I which encodes the fully functional CD40 receptor, the presence of three 
alternative CD40 mRNA isoforms has been confirmed. The major alternative isoform 
(type II) lacks exon 6 and encodes a soluble CD40 (sCD40) protein. Unlike other protein 
variants, type II which is also known as sCD40-6 retains three cysteine rich domains 
essential for binding to CD40L (Figure 1). Therefore, even though sCD40 generated 
from isoform II cannot signal, it can still bind to CD40L. Hence, it has the capacity to act 
as a decoy receptor which is a receptor that can structurally bind to a ligand but cannot 
activate it. Soluble CD40 can also be generated by the proteolytic cleavage of membrane 
CD40 via TNF-alpha-converting enzyme (TACE) and is likely to have clinical relevance 
(Eshel et al., 2008; Tone et al., 2001). For instance, elevated sCD40 levels have been 
reported in the serum of uremic patients which were decreased after normalization of 
kidney function (Contin et al., 2003). Increased sCD40 levels have also been associated 
with hematological malignancies (Hock et al., 2004) and Alzheimer’s disease (Buchhave 
et al., 2009 and Ait-ghezala et al., 2008). 
At the post-translational level CD40 is regulated by nitration of tyrosine residues. The 
tyrosine at position 82 has been shown to be particularly susceptible to nitration in resting  
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Figure 1: Human CD40 receptor isoforms. (A) Gene structure of CD40 with 9 exons 
depicted as boxed structures. (B) CD40 isoform mRNA structures with lines and arrows 
indicating the splice sites and stop codons respectively. (C) Predicted translation product 
of the mRNA isoforms. H I, H II and H III denote human I, II and III isoforms 
respectively. Isoform I is the main CD40 receptor. Isoform II is the major alternative 
isoform with three cysteine-rich domains while in isoform III the intracellular regions are 
replaced by distinct 19 amino acids. (Image modified from Tone et al., 2001).  
 
and stretched endothelial cells. Consequences of tyrosine nitration include functional 
inactivation of CD40 followed by its targeting for proteasomal degradation (Wagner et al., 
2011). There is also some evidence that CD40 can undergo S-nitrosylation, which is the 
binding of nitric oxide to thiol (SH) residues. It is possible that S-nitrosylation of CD40 
augments the inflammatory response and its clinical relevance has been demonstrated in 
sepsis (Godoy et al., 2010).  
2.3 Atherosclerosis 
Atherosclerosis and its related complications such as coronary heart disease (CHD), 
myocardial infarction, heart failure and ischemic stroke are one of the leading causes of 
global morbidity, mortality and disability. Currently cardiovascular diseases (CVD) 
represent 31% of deaths worldwide but by 2020 this figure is expected to rise to 40%, 
enabling CVD-related mortality to exceed that of infectious diseases (World Health 
Organization, 2014). Atherosclerosis progression is asymptomatic and can be silent for 
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decades until it manifests itself in the form of angina or in more advanced cases as 
myocardial infarction or stroke (Biros et al., 2008). Therefore identification and early 
treatment of susceptible individuals is a feasible strategy for reducing the global burden 
of this chronic condition. 
Atherosclerosis primarily affects large and medium sized arteries (Napoli et al., 1997). 
According to the response to injury hypothesis, the earliest event in atherosclerosis is an 
injury to the endothelium which precedes the development of atherosclerotic lesions. 
Endothelial injury can arise due to a number of factors such as physical stress, generation 
of reactive oxygen species and elevated levels of LDL, VLDL and glucose. A major 
contribution is made by altered hemodynamics, i.e. disturbed blood at arterial 
bifurcations and curves which weakens the anti-inflammatory defense of the endothelium, 
inducing endothelial dysfunction and thereby resulting in the early and maintained influx 
of proinflammatory leukocytes into the subendothelial spaces. Initially monocytes are 
recruited into the developing fatty streak which is composed of lipid-laden vascular 
smooth muscle cells, followed by Th1 cells (Bonetti et al., 2003; Ross, 1993; Widlandsky 
et al., 2003). Recently, the presence of polymorphonuclear neutrophils has also been 
confirmed in atherosclerotic lesions of human and murine origin (Drechsler et al., 2010; 
Ionita et al., 2010).   
Collagen and matrix molecules produced mainly by activated vascular smooth muscle 
cells form the fibrotic cap underneath the endothelial cells which is eroded by the matrix 
metalloproteinases released following the interaction of CD40L expressing Th1 cells and 
CD40 expressing macrophages, leading to the formation of a rupture-prone 
atherosclerotic plaques. In addition to CD40L on Th1 cells, sCD40L is also shed from 
platelets (Elhage et al., 2003, Gerdes et al., 2016; reviewed by Tse et al 2013. In this 
environment CD40-CD40L interactions drive a plethora of proinflammatory responses 
which are reviewed below. 
2.3.1 CD40-CD40L interactions in endothelial dysfunction and atherosclerosis 
Inflammation is a protective cellular immune response to invasive pathogens, injury and 
irritation. However, continuous exposure to proinflammatory stimuli leads to chronic and 
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persistent inflammation which is a widely accepted hallmark of atherosclerosis and is 
implicated in all stages of its development and progression. 
Endothelial dysfunction is an early marker for atherosclerosis. It is described as a shift of 
the endothelium from a quiescent towards a prothrombotic and proinflammatory 
phenotype (Lüscher and Barton, 1997). The endothelium is a selectively permeable 
barrier between the blood and the vessel wall. It fulfils essential functions including 
blood flow regulation and maintenance of vascular tone. Under physiological conditions 
it is an antithrombotic surface to which mononuclear cells cannot attach due to a lack of 
adhesion molecules. However, this condition is not maintained during disturbed blood 
flow which can be caused by inflammation, low shear stress and cardiovascular risk 
factors, and is aided by genetic predisposition (Asakura et al., 1990; Cataruzza et al., 
2004; Celermayer, 1993; Libby et al., 2002). 
CD40-CD40L interactions promote inadequate endothelial cell activation and ensuing 
dysfunction (Figure 2). During inflammation, cytokines such as TNF-α, IFN-γ, 
interleukin (IL)-1, -3 and -4 are released from activated monocytes and T helper cells. 
These cytokines induce CD40 expression on endothelial cells, which in an atherosclerotic 
context may be aggravated by oxidized LDL. The endothelial cells then interact with 
CD40L bound to T cells or released as a soluble form from activated platelets (reviewed 
by Antoniades et al., 2009). 
Furthermore, CD40-CD40L interactions facilitate leukocyte adhesion to the endothelial 
cell surface via upregulation of adhesion molecules such as vascular and intracellular cell 
adhesion molecule (VCAM-1, ICAM-1) and E-selectin as well as P-selectin (Karmann et 
al., 1995; Hollenbaugh et al., 1995). The penetration of the adhered leukocytes is 
facilitated by monocyte chemoattractant protein-1 (MCP-1), which is a key chemokine 
primarily released from stretched vascular smooth muscle cells (Demicheva et al., 2008) 
and also upregulated by endothelial CD40-CD40L interactions. It provides a signal to 
recruit circulating monocytes to the vascular endothelium where they transmigrate and 
differentiate into macrophages and foam cells (Wagner et al., 2004).  
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CD40 signal transduction also leads to increased expression of interleukins, matrix 
metalloproteinases and tissue factors. These changes are accompanied by a decrease in 
the expression, activity and stability of the cardio-protective endothelial nitric oxide 
synthase. All together these changes confer an activated proatherogenic phenotype to the 
endothelium, which is strongly implicated in chronic inflammatory diseases particularly 
atherosclerosis (Pluvinet et al., 2008). 
 
 
 
 
 
 
 
 
 
 
  Introduction 
17 
 
  
 
Figure 2: CD40-CD40L interactions in atherothrombosis: A simplified illustration of 
the impact of CD40-CD40L interactions in the context of atherosclerosis; CD40L 
cleaved and released from activated platelets binds to CD40 expressed on endothelial 
cells. The resulting expression of transcription factors such as NFkB and activator 
protein-1 (AP-1) leads to endothelial activation through upregulation of chemokines 
(MCP-1) and adhesion molecules (VCAM-1, E-selectin and I-CAM). Monocytes are 
attracted to the endothelial surface, adhere and transmigrate into the subendothelial 
region. In activated vascular smooth muscle cells and macrophages, especially upon 
interaction with infiltrating Th1 cells, there is upregulation of matrix metalloproteinase 
(MMP) expression which results in plaque instability through collagen degradation. 
Additionally, foam cell formation is promoted by uptake of oxidized-low density 
lipoprotein by macrophages and VSMCs. Altogether the consequences of CD40-CD40L 
interactions create a pro-thrombotic environment favoring plaque formation and 
disruption which can lead to vessel occlusion (Figure is taken from Antoinades et al., 
2009). 
 
2.3.2 Atherosclerosis and rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory exaggerated immune response likely 
mediated via Th1 cells which primarily affects the small joints in the hands and feet. The 
correlation between RA and CVD is indisputable. Cardiovascular mortality is 50% higher 
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in RA patients as compared to non-RA groups (Avina-Zubeita et al., 2009). Additionally, 
the risk for myocardial infarction (MI) is two-fold higher in RA patients, which is 
comparable to the risk imparted by type II diabetes (Solomon et al., 2003). There is a 
strong possibility that the underlying reason is accelerated inflammation since RA is 
characterized by inflammation which promotes and exacerbates atherosclerosis (reviewed 
by Yang et al., 2016). CVD incidence is also enhanced in other systemic inflammatory 
diseases such as systemic lupus erythematosus (SLE) (Nikpour et al., 2003) and 
inflammatory bowel disease (Singh et al., 2014). There are high similarities in the 
proinflammatory processes in an atherosclerotic plaque and the hypertrophied synovium 
(pannus) in RA. C-reactive protein is a marker for both RA (Ridker et al., 1998) and 
CVD (Del Ricon et al., 2003). In both conditions, cytokines primarily TNF-α and IL-1 
are elevated, accompanied by increased expression of adhesion molecules which promote 
leukocyte extravasation. TNF-α reduces nitric oxide (NO) bioavailability in the vessel 
wall by decreasing the half-life of endothelial nitric oxide synthase mRNA and thereby 
impairs NO-mediated endothelium-dependent anti-inflammatory responses, setting the 
stage for endothelial dysfunction (reviewed by Zhang et al., 2009).  
Endothelial activation and ensuing dysfunction is a well-known driver of inflammation in 
atherosclerosis. Similarly, its presence has been reported at various stages of RA 
(reviewed by Steyers and Miller, 2014). Animal models of RA also exhibit early 
endothelial dysfunction. For instance, in collagen-induced arthritis in mice as well as in a 
sheep model, there is considerably greater impairment of endothelium-dependent NO 
release as compared to non-diseased controls (He et al., 2013; Dooley et al., 2014). Also, 
aortic endothelium isolated from the same mouse model exhibits elevated VCAM-1 
expression (Denys et al., 2014). Hence it is not farfetched that the underlying factor 
integrating RA and CDV is an inadequately activated endothelium that precedes 
atherosclerosis.  
2.3.3 Genetic risk of atherosclerosis 
Atherosclerosis has a complex phenotype arising from the interplay between genetic and 
environmental factors. Epidemiological investigations including the Framingham study 
have identified family history as an independent risk factor of fatal cardiac events 
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(Yarnell et al., 2003). The Swedish Longitudinal Heart study has shown a high relative 
risk of death by coronary artery disease (CAD) in monozygotic and dizygotic male and 
female twins when one of the pair has suffered from a cardiac event prior to age 65 
(Zdravkovik et al., 2002). In addition, primary risk factors such as diabetes, dyslipidemia 
or hypertension also have a significant individual genetic component. These observations 
place the heritability factor of CAD between 50-60% (Peden and Farrall, 2011). However, 
due to the polygenic and multifactorial nature of CAD, precise identification of the 
molecular genetic architecture has remained elusive.  
The most common type of genetic variation in the human genome is represented by 
single nucleotide polymorphisms (SNP), i.e. single DNA base changes that occur rather 
frequently and can be a marker of disease development and progression. Recent advances 
in technology and data analysis made possible by the Human Genome Project have led to 
the development of genome wide association studies (GWAS). In GWAS millions of 
SNPs are simultaneously examined in thousands of case-control populations 
(https://www.ebi.ac.uk/gwas/). 
While GWAS is a bias-free method, another way of harnessing SNPs to understand 
genetic associations is the candidate gene approach in which pre-specified genomic 
regions are analyzed to determine association with disease states. A high throughput 
candidate gene approach in humans analyzing data obtained from 15,596 CAD cases and 
34,992 controls using the cardiovascular gene-centric 50K SNP array customized for 
CAD has implicated several novel genes including lipase A (LIPA), interleukin 5 (IL-5), 
Tribbles homologue-1 gene (TRIB-1) and ATP-binding cassette sub-family G proteins 
(ABCG-5 and 8) with increased CAD risk. Combined with data from the 
CARDIoGRAM (Coronary Artery Disease Genome Wide Replication and Meta-analysis), 
the association of 33 loci with common variants significantly influencing the risk of CAD 
was confirmed (Brendan et al., 2008, Butterworth et al., 2009). However, these studies 
account for only approximately 10% of the total genetic risk. This is likely because of the 
stringent threshold for GWAS studies (P<5x10
-8
).  
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2.4 Single nucleotide polymorphism and disease susceptibility 
SNPs are the most common form of genetic variation and occur at a frequency of once 
per every 300 nucleotides. There are approximately one million known SNPs in the 
human genome. A vast majority of them have no pathophysiological relevance. However, 
some occur within, or in linkage disequilibrium with other SNPs, in the regulatory 
regions of genes. As such they can directly affect disease development by influencing 
gene expression and function (Van der Broeck et al., 2014). For instance, a G to A 
transition at position 75 of the apolipoprotein A1 gene promotor is associated with early 
onset Alzheimer’s disease potentially through influencing cholesterol metabolism 
(Helbecque 2008). Another promoter polymorphism present in the gene for NOS3, the 
endothelial isoform of NO synthase (-786 C/T), is an independent predictor of vascular 
inflammatory diseases including CHD and RA through inducing endothelial dysfunction 
(Cataruzza et al., 2004; Melchers et al., 2006). Following sequencing of the human 
genome, a database characterizing more than a million genetic variants in world 
populations has been organized by the human genome project (HGV) in collaboration 
with the HapMap project  (International HapMap Consortium, 2005). 
2.4.1 The -1C/T CD40 single nucleotide polymorphism 
In 2002, linkage analysis identified chromosome 20q11 as a susceptibility locus for the 
autoimmune condition known as Graves’ disease. Sequencing of the entire CD40 gene, 
which maps to the specified locus, identified a cytosine to thymine transition one base 
pair upstream of the initiating AUG codon which was classified as a -1C/T CD40 SNP 
(Figure 3). This SNP is located in the Kozak consensus sequence, which is a region of 6-
8 nucleotides surrounding the initiating codon. A conserved Kozak sequence is necessary 
for optimal protein translation (Kozak 1984 and 1986). In Graves’ disease, patients 
present a preferential transmission of the C allele (Tomer et al., 2002). A follow up study 
investigating a possible mechanism for this phenotype showed an association of the C 
allele with higher CD40 protein expression in B cells as well as increased translation in 
an in vitro system, indicating that the C allele predisposes towards Graves’ disease by 
increasing CD40 levels (Jacobson et al, 2005). This SNP is also implicated with other 
auto-immune conditions including the prototypic autoimmune disease systemic lupus 
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erythematosus (Chen et al., 2015; Wu et al., 2016). In light of the importance of CD40-
CD40L interactions in inflammation, the -1C/T CD40 SNP has also been studied in 
relation with diseases associated with increased inflammatory responses such as CHD, 
and the C allele has been consistently implicated as a risk factor (Tian et al., 2010; Yan et 
al., 2010; Yun et al., 2014).  
 
Figure 3: Location and impact of the -1C/T SNP of the CD40 gene. (A) The 
chromosomal location of the -1C/T CD40 is illustrated. The CD40 gene is located on 
chromosome 20 (q12-q13.2). One base pair upstream of the initiation codon a cytosine 
or a thymine can be present. This is referred to as the -1C/T CD40 SNP or Rs1883832. 
5’UTR refers to the untranslated region (B) Mechanism of action. The -1C/T SNP affects 
the initiation of translation therefore both alleles are transcribed equally by RNA 
polymerase II. The initiation of translation is more effective in the C allele resulting in a 
greater quantity of translated product (adapted from Jacobson et al., 2005 and Yun et al., 
2014).  
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2.5 Aim of the study 
The proinflammatory response triggered by CD40-CD40L interactions makes a 
significant contribution to endothelial dysfunction, which is the underlying basis of 
chronic inflammatory conditions, like cardiovascular and rheumatic diseases. Given the 
importance of these interactions, even slight imbalances in expression would further 
enhance immune dysregulation and prolong inflammation. A common genetic 
polymorphism in the CD40 gene which is a C to T variation at position -1 of the 5’ UTR 
is known to influence CD40 gene expression in various cell types and is a risk factor for 
autoimmune and immune-inflammatory diseases. This study investigated if the -1C/T 
SNP of the CD40 gene is a genetic risk factor for susceptibility towards endothelial 
dysfunction by influencing endothelial CD40 gene expression and function. Considering 
that endothelial dysfunction is an early predictor for atherosclerosis, we further 
hypothesized that the -1C/T SNP may influence susceptibility to pathologies in which 
atherosclerosis is dominant, namely CHD, and related inflammatory diseases such as 
rheumatoid arthritis. To test this hypothesis, allele frequencies for the -1C/T SNP of the 
CD40 gene were compared in non-diseased controls and patients with CHD, psoriatic and 
rheumatoid arthritis. Since activation of the CD40 receptor and downstream signaling 
maybe regulated by its soluble form, we further investigated if sCD40 levels were 
influenced by the –1C/T SNP and its implications in a CHD context. The main aims of 
this thesis are summarized below: 
1. To investigate the distribution of the -1C/T SNP in the local population of Baden-
Württemberg and compare the allele and genotype frequencies with those reported by the 
1000 Genome project. 
2. To analyze whether the -1C/T SNP can be functionally considered as a risk factor for 
inducing endothelial dysfunction via influencing CD40 expression and signaling in 
endothelial cells under baseline and proinflammatory conditions. 
3. To determine if the -1C/T SNP is a true risk factor for CHD and related inflammatory 
arthritic conditions in a hospital based case-control study. 
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4. To evaluate the clinical relevance of sCD40 in a CHD context and analyze its possible 
association with the -1C/T SNP, namely the CC genotype. 
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3. MATERIALS 
3.1 Buffers and Solutions 
Table 1: Composition of buffers and solutions 
Buffer/Solution Composition 
Agarose gel electrophoresis 
Loading buffer 
 
 
 
 
 
Running buffer 
 
 
 
10 mM Tris HCl, pH 7.5 
10 mM EDTA, pH 8.0 
30% Glycerol 
0.01% Bromophenol blue 
0.01% Xylene green 
 
450 mM Tris 
450 mM Boric acid  
20 mM EDTA, pH 8.0 
FACS buffer Ice-cold DPBS and 10% FCS 
Protein extraction 
Lysis buffer (whole cell 
extract) 
 
 
 
 
 
 
Pefabloc 
 
 
Protease inhibitor mixture 
 
 
10 mM Hepes, pH 7.9  
10 mM KCl  
0.1 mM EDTA 
 0.1 mM EGTA  
0.1 M DTT  
50 µM Pefabloc  
25 µM Protease inhibitors 
 
15 mM HEPES buffer, pH 7 
4 4 % Pefabloc®-SC 
 
1 % Pepstatin A in 20 DMSO  
80 % 15 mM Hepes, pH 7.4  
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Protease inhibitor mixture 
 
1 % Leupeptin in 20 % DMSO  
80 % 15 mM Hepes, pH 7.4 
Phosphate-buffered Saline 
(PBS) 
8.0 g NaCl   
0.2 g KCl   
1.44 g Na2HPO4   
0.2 g KH2PO4 
SDS-PAGE 
Blocking buffer 
 
Running buffer 
 
 
 
Stripping buffer 
 
Transfer buffer 
        
5% milk powder in TBST    
 
 248 mM Tris-HCl, pH 8.7  
 192 mM Glycine 
  35 mM SDS in 2 L water  
 
0.2 M NaOH 
 
25 mM Tris 
192 mM glycine, pH 8.3                                                                         
Tris-buffered saline (TBS) 
 
 
 
TBS-T 
248 mM Tris-HCl pH 8.3   
192 mM glycine dissolved in 2 
litre H2O 
 
TBS+0.05% Tween®20 
 
3.2 Chemicals and reagents  
Table 2: Chemical and reagents used in this work 
Chemicals and reagents Supplier 
Agar-Agar Carl Roth 
Ampicillin Sigma-Aldrich 
Ammonium persulfate Carl Roth 
  Materials  
26 
 
Chemicals and reagents Supplier 
Bovine Serum Albumin Sigma-Aldrich 
Calceim AM Molecular Probes  
Life Technologies 
Dispase Gibco, Life 
Technologies 
Dithiothreitol (DTT) Carl Roth 
DNA ladders Thermo Scientific 
D-Phosphate-buffered saline 
solution 
Gibco, Life 
Technologies 
Endothelial cell growth medium PromoCell 
Endothelial cell growth supplements PromoCell 
EDTA (Ethylenediaminetetraacetic 
acid) 
PanReac AppliChem 
Ethidium bromide Carl Roth 
Fungizone Gibco, Life 
Technologies 
Gelatin Merck Millipore 
Hank’s balanced salt solution Gibco, Life 
Technologies 
Heat inactivated fetal bovine serum Gibco, Life 
Technologies 
HEPES Sigma-Aldrich 
Luminata
TM
  and Luminata
TM
 Forte Merck Millipore 
Methanol Sigma-Aldrich 
Oligo dT Qiagen 
Penicillin Gibco, Life 
Technologies 
Pefabloc Sigma-Aldrich 
Pepstatin A Sigma-Aldrich 
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Chemicals and reagents Supplier 
Polyacrylamide Carl Roth 
Precision Plus Protein Standard
TM
 Bio-Rad Laboratories 
Restriction enzyme (NcoI) New England Biolabs 
RPMI 1640 medium Invitrogen 
Sodium dodecyl sulfate (SDS) Serva Electrophoresis 
Streptomycin Gibco, Life 
Technologies 
TEMED 
(Tetramethylethylenediamine) 
Carl Roth 
Tween 20 Carl Roth 
Tris Carl Roth 
Triton-X 100 Sigma-Aldrich 
Taq Polymerase Bioron 
 
3.3 Consumables 
Table 3: Materials utilized in the study 
Materials Company 
Cell culture dishes Techno Plastic Products 
(TPP) 
Cell culture flasks   
 
Sarstedt 
 
Cell culture plates 
Cell scraper 
PCR tubes 
Pipette tips 
Serologic pipettes 
PVDF Transfer membranes Merck Millipore 
Round bottom glass FACS tubes Falcon-Corning 
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3.4 Kits: 
Table 4: Kits used in this work 
Kit Catalog 
Number 
Supplier 
Omniscript RT Kit 205113 Qiagen 
 QuantiTect SYBR Green R 
PCR kit 
204143 
RNA Isolation (RNeasy Mini 
Kit) 
74104 
Quantikine ELISA  
CD40 
CCL2/MCP-1   
sE-selectin/CD62E 
 
DCCD40 
DCP100 
DSLE00 
R&D 
 
3.5 Miscellaneous Equipment 
Table 5: Miscellaneous equipment utilized 
Equipment Model Supplier 
Agarose gel 
electrophoresis 
power supply 
PowerPack 25 Biometra  
CO2 incubator Innova 4230 
and CO-170 
Heraeus Instruments 
Centrifuge Universal 32 Hettich Zentrifugen 
Digital Imaging 
System 
ImageQuant 
LAS 4000 mini 
GE Healthcare 
Dry block heater HBT-1131 Haep Labor Consult 
FACS machine 
 
BD 
FACSCanto II 
 
BD Biosciences 
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Equipment Model Supplier 
Fluorescence 
microscope 
ScanR Inverted 
Microscope 
Olympus 
Image analyzer Gel Doc® XR 
Imager 
Bio-Rad 
Lab pH meter  pH 720 InoLab® 
Laminar flow HS18 Hera safe Heraeus Instruments 
Light cycler®  480 software, 
version 1.5 
Roche 
Light microscope Axiovert 25 Carl Zeiss 
Microplate 
spectrophotometer 
PowerWave XS Bio Tek Instruments 
Mini transfer 
chamber 
Mini Trans-
Blot® 
Bio-Rad 
NanoDrop 
spectrophotometer 
ND-1000 Thermo Fisher 
Scientific 
PCR cycler Thermocycler Biometra 
Refrigerated 
centrifuge 
Mikro 22 Hettich Zentrifugen 
SDS-PAGE 
system 
Mini-Protean® 
Tetra Cell 
BioRad 
Ultrasonic 
homogenizer  
UP50H Hielscher 
Ultrasonics  
Water bath Ecotherm E11 Dinkleberg 
Analytics 
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3.6 Primer sequences (qRT-PCR and conventional PCR) 
Table 6: Primers and their sequences 
Gene 
product 
Primer sequence  
(Direction 5’ to 3’) 
Annealing 
Temperature  
CD40 For  
GCATGCAGAGAAAAACAGTACCT 
Rev GTGCAGTCACTCACCAGTTTCT 
60° C 
CD40 ∆6 
 
For 
GGGGTCAAGCAGATTGGTCCCCA 
Rev 
AGACCAGCACCAAGAGGATGGCA 
60° C 
E-selectin For  TTCGCCTGTCCTGAAGGATG 
Rev TCAGTTGAAGGCCGTCCTTG 
60° C 
GAPDH 
 
For  CCACTCCTCCACCTTTGAC 
Rev ACCCTGTTGCTGTAGCCA 
60° C 
HPRT For  CAAGCTTGCTGGTGAAAAGGAC 
Rev 
GTCAAGGGCATATCCTACAACAAA 
59° C 
MCP-1 
 
For  
CAAACTGAAGCTCGCACTCTCGCC 
Rev 
GCAAAGACCCTCAAAACATCCCAGG 
63° C 
VCAM-1 For  CATGGAATTCGAACCCAAACA 
Rev 
GACCAAGACGGTTGTATCTCTGG 
53° C 
Genotyping primer 
CD40  
(-1C/T SNP) 
For CCTC TTCCCCGAAGTCTTCC 
Rev GAAACTCCTG CGCGGTGAAT 
 
61° C 
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3.7 Recombinant proteins 
Table 7: Concentrations of recombinant proteins used 
Recombinant 
protein 
Concentration Company 
IFN-γ 100 U/ml R&D systems 
MCP-1/CCL2 30 ng/ml R&D systems 
Soluble trimeric 
CD40Ligand 
200 ng/ml Enzo Life Sciences 
TNF-α 1000 U/ml Biomol GmbH 
Antibodies Dilution Company 
Immunoblotting 
Rabbit polyclonal 
anti-CD40(C-20) 
 
Mouse monoclonal 
anti-beta-actin 
 
 
1:500 
 
 
1:2000 
 
Santa Cruz 
Biotechnology 
 
Abcam 
Flow cytometry 
FITC- mouse anti-
human CD40 
 
PE mouse anti-
human CD106 
 
FITC mouse IgG1 
(κ Isotype control) 
2μl/test BD Pharmingen 
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4. METHODS 
4.1 Cell culture and isolation 
4.1.1 Human umbilical vein endothelial cells (HUVEC) 
Human umbilical vein endothelial cells were isolated from fresh umbilical cords obtained 
from the University Clinic Heidelberg with the permission of the local Ethics Committee 
(S-383/2013). For isolation a cannula was inserted into the ends of the umbilical vein and 
blood was cleared with 20 ml of D-PBS buffer. For endothelial cell isolation, the 
umbilical veins were filled with dispase solution (3.1 g/l) through the cannula whose ends 
were tied. After 30 min incubation at 37°C, the contents were centrifuged at 1000 rpm for 
5 min. The cell pellet was re-suspended in endothelial cell growth medium containing 
supplements, antibiotics and antimycotic agents. The isolated cells were cultured in a 
CO2 incubator at 37°C on 60 mm polystyrene dishes coated with 2% (w/v) gelatin. Cells 
were passaged once (P1) on gelatin coated 6 well dishes. 
4.1.2 THP1 cells 
THP1 is a human acute monocytic leukemia cell line (ATCC® TIB-202™) commonly 
used to investigate the function and regulation of monocytes and macrophages in the 
cardiovascular system. THP1 cells were maintained in RPMI 1640 medium 
supplemented with 10% heat-inactivated FBS and 1% of penicillin/streptomycin at 37 °C 
and 5% CO2. Cells were maintained at a density between 1x10 
5
 and 5x10
5
 cells/ml. Cells 
were sub-cultured every two-three days (density 7-8x10 
5 
cells/ml).  
4.2 Cell treatments 
HUVECs were stimulated with sCD40L (200ng/ml) for 8 or 24 hours for measuring 
changes in mRNA and protein respectively. For cytokine priming, the cells were 
incubated with a mixture of TNF-α (1000U/ml) and IFN-γ (100 U/ml) for 16 hours with 8 
(mRNA) or 24 hours (protein) further culture with sCD40L. To analyze the effect of 
cytokine priming without sCD40L, the cells were cultured with TNF-α and IFN-γ for 24 
hours (mRNA) or 40 hours (protein). 
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4.3 Monocyte adhesion assay 
HUVECs cultured for 48 hours on gelatin coated 12 well plates were stimulated for 14 
hours with 200 ng/ml sCD40L. THP1 cells (2x10
5
) were labelled with Calcein-AM 
(2μM) by incubation at 37°C for 30 mins with rotations every 10 minutes. The labelled 
cells were centrifuged at 1000 rpm for 5 minutes and resuspended in 1 ml EC medium. 
HUVECs were washed to remove the stimuli and overlaid with the THP-1 cells for 2 
hours at 37°C. The non-adherent cells were removed by careful washing (5 times) with 
pre-warmed D-PBS. The numbers of adherent cells were imaged immediately (Figure 4) 
using a fluorescence microscope (Olympus ScanR) and cells were counted in multiple 
planes using the CellSens software (Version 1.12).  
 
Figure 4: Monocyte adhesion to the endothelial monolayer. THP-1 adhesion to 
the endothelial monolayer before (A) and after sCD40L stimulation (B). THP-1 
adhesion to the different genotypes of the -1C/T SNP of the CD40 gene was 
analyzed using this set-up. 
4.4 Genomic DNA extraction from human blood 
DNA was extracted from whole blood using Qiagen DNA Mini Kit as per the 
manufacturer’s protocol. This kit uses a silica membrane spin column that selectively 
adsorbs DNA in the sample while impurities and contaminants are eluted using low salt 
buffers. Pure DNA was eluted in 30 μl elution buffer and its purity was assessed by the 
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ratio of A260/A280 which was determined spectrophotometrically using the NanoDrop ND-
1000 (PeQlab Biotechnology, GmbH). Samples with a ratio between 1.7 and 1.9 were 
genotyped for the -1C/T CD40 SNP. 
4.5 RNA extraction from cells 
To isolate RNA from adherent cells, they were rinsed with cold D-PBS or Hank's 
balanced salt solution (HBSS) and lysed with 350 μl RNA lysis buffer supplemented with 
1% β-mercaptoethanol. Suspension cells (THP1 cells) were centrifuged at 1000 rpm for 5 
mins and lysed with the same method as for the adherent cells. Total RNA was extracted 
using Qiagen RNEasy extraction kit following the manufacturer’s protocol briefly 
outlined below. Column silica membranes form the basis of this method. The lysed 
samples were mixed with an equal volume of 70% ethanol to facilitate binding of RNA to 
the silica membranes. Washing steps with buffers supplied ensure the elution of pure 
RNA after DNA digestion and elimination of other cellular components. Purity and 
concentration of the RNA eluted in 30 μl of RNase free water was analyzed 
spectrophotometrically. For assessment of purity the ratio of absorbance readings at 260 
and 280 nm (A260/A280) was analyzed. Samples within a ratio of 1.9 to 2.1 were analyzed 
further. 
4.6 Reverse transcription and cDNA synthesis  
The Qiagen Omniscript® Reverse Transcription Kit was used for the transcription of the 
RNA template to complementary DNA (cDNA), according to the manufacturer’s 
instruction. Briefly, 100 ng of the template (12 μl) was incubated with a master mix 
composed of reverse transcriptase enzyme, RNase inhibitor which inhibits RNases from 
the human placenta as well as RNase A,B and C, and a primer mix containing dNTPs and 
random primers to facilitate transcription from all regions including the 5´ untranslated 
region. The volume was made to 20 μl with RNase free water and the mixture was heated 
at 56°C for 1 hour. After cooling the mixture on ice, the resulting cDNA was diluted 1:10 
and used as a template for conventional or RT-qPCR.  
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4.7 Real-time quantitative reverse transcription polymerase chain reaction (RT-
qPCR) 
RT-qPCR reactions were carried out using the QuantiTect SYBR Green® Kit (Qiagen, 
Germany) with the LightCycler 1.5 instrument (Roche Diagnostics, Germany). A master 
mix of 20 μl was prepared, the constituents of which are listed in table 8. The annealing 
temperatures varied according to the primer pairs being used for amplification and are 
tabulated in table 6. Experiments were carried out in duplicates and the Ct values of the 
technical duplicates were typically within 0.3 cycles. To adjust for inter-experimental 
variability changes in gene expression were normalized to housekeeping genes: GAPDH 
or HPRT-1 (Primer sequence from Raychaudhuri et al., 2008). Ct values of these genes 
did not vary considerably between the control and stimulated conditions. Changes in gene 
expression were analyzed by relative quantification which is based on the comparative Ct 
method, where Ct denotes the cycle number required for exceeding the fluorescence 
threshold (Livak et al., 2001). Fold changes in gene expression were calculated by 
computing the ratio of the Ct values of target and housekeeping genes under untreated vs 
treated conditions. 
Gene expression was quantified by a mathematical model which enables relative 
quantification of the target gene by comparison to a reference gene (Pfaffl, 2001). The 
gene transcript of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an 
internal standard. GAPDH is widely considered to be a housekeeping gene since it is 
essential in glycolysis and has a stable expression across various cells and experimental 
conditions. Consequently, it is commonly used as a reference gene for mRNA and protein 
normalization (De Kok et al., 2005; Sikand et al., 2012). Additionally, selected 
experiments were also compared to mRNA expression of hypoxanthine guanine 
phosphoribosyl transferase (HPRT), an enzyme essential for purine generation, and also a 
standard housekeeping gene for use as endogenous standard (Lee et al., 2002). The ratio 
was calculated as follows: 
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𝑟𝑎𝑡𝑖𝑜 =
(𝐸𝑡𝑎𝑟𝑔𝑒𝑡)
𝛥𝐶𝑃
𝑡𝑎𝑟𝑔𝑒𝑡(𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑠𝑎𝑚𝑝𝑙𝑒)
(𝐸𝑟𝑒𝑓)
𝛥𝐶𝑃
𝑟𝑒𝑓(𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑠𝑎𝑚𝑝𝑙𝑒)
 
E target, E ref = amplification efficiencies of the target and reference gene 
CP target, CP ref = fluorescence crossing points 
 
The PCR amplification efficiency was assessed by the methods published by Pfaffl in 2001 
(Etarget and Eref ≈ 2). CP values for each transcript were determined by setting a threshold in 
the segment of the highest fluorescence intensity increase using the Light cycler software 
(Version 1.5, Roche). 
Table 8: Composition of the reaction mixture for RT-qPCR 
Component Volume (μl) 
cDNA (20 ng) 5 
Primers (10-20 μM) 
(Forward and Reverse) 
2 
 
SYBR green 10  
Water  3  
 
4.8 Conventional PCR 
Semi-quantitative PCR was used for genotyping the -1C/T CD40 SNP and isolating 
soluble CD40 from HUVEC cDNA. The composition of the PCR reaction mixture is 
outlined in table 9 and it was amplified in an automated thermocycler (Biometra), for 
which the cycling parameters are presented in table 10. 
Table 9: Composition of the reaction mixture for PCR 
Component Volume (μl) 
PCR buffer (10X) 5 
Primers (10μM) 
(Forward and reverse) 
1 
dNTPs (10mM) 4 
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Table 10: PCR program for the genotyping of the -1C/T SNP of the CD40 gene 
Step Temperature       
(°C) 
Time 
Pre-
denaturation 
94 5 min 
Denaturation 94 30 s 
Annealing 61 45 s 
Synthesis 72 45 s 
Extension 72 10 min 
 
4.9 Restriction fragment length polymorphism analysis 
For genotypic analysis of the -1C/T CD40 SNP, PCR-based restriction fragment length 
polymorphism (PCR-RFLP) analysis was performed. Genomic DNA extracted from 
umbilical arteries, human patients and healthy control subject’s blood was genotyped. A 
320 bp fragment of the 5’ untranslated region surrounding the SNP was amplified by 
PCR and digested for 1 hour at 37°C with the restriction enzyme NcoI. The resulting 
fragments were visualized on an agarose gel and the genotype determined according to 
the band pattern obtained which was indicative of the genotype (Figure 5). 
DNA 3 
Taq polymerase 0.2 
Water 36.8 
Total 50 
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Figure 5: Representative 3 genotypes of the -1C/T SNP of the CD40 gene. Genotyping 
was performed by polymerase chain reaction-restriction fragment length analysis of 
genomic DNA. 
4.10 Agarose gel electrophoresis 
Agarose gel electrophoresis is a molecular biology technique for the size based separation 
of DNA fragments, which migrate towards the positive electrode depending upon the size 
of the agarose gel. This technique was utilized for restriction fragment length 
polymorphism (RFLP) and to confirm the presence of the correct PCR product after 
amplification. Gels with a density of 2% were prepared by dissolving 3 g agarose in 150 
ml TBE buffer supplemented with 4 μl ethidium bromide for visualization of the DNA 
fragments. Samples consisting of either PCR products or restriction digests were mixed 
with 6μl loading dye and electrophoresed at 120 V for 60 mins. For verification of the 
DNA size fragments standard DNA ladders were used. The resolved samples were 
visualized using the Gel Doc XR+ system and the Quantity One software (Version 4.6.9, 
Bio-Rad Germany) was used for data analysis. 
4.11 Protein extraction 
For total cellular protein isolation, cells were rinsed twice with ice cold HEPES buffer 
and scraped in 1.5 ml HEPES, followed by centrifugation at 3000 rpm for 5 mins at 4°C. 
The pellet was lysed in 150 μl lysis buffer containing protease inhibitors and Pefabloc to 
protect the samples from proteolysis, and dithiothreitol to prevent protein oxidation. 
Cellular contents were disrupted by exposure to sound waves of 30 Hz in short bursts of 
10 sec. Samples were kept on ice in between sonication to regulate the heat generated. A 
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second centrifugation step ensured the removal of nonhomogenized cells and cellular 
debris. 
Light absorbance of the samples at 595 nm wavelength was measured using the Bradford 
dye reagent in a colorimetric assay for estimation of the protein concentration. Increase in 
absorbance is directly proportional to the protein concentration. Standard curves were 
generated with known bovine serum sample standards and the samples were immediately 
frozen in liquid nitrogen and stored at -80°C for further analysis.  
4.12 Immunoblotting 
Separation of protein samples was achieved using SDS-PAGE. 10% denaturing gels 
overlaid with 4% stacking gel (table 11) were freshly prepared for polymerization. Total 
protein (20μg) was denatured by heating at 95°C for 5 mins with 4X sample loading 
buffer (Roth) and loaded onto 1.5mm thick gels. A vertical system (Mini-Protean Tetra 
Cell, Bio-Rad) was utilized for electrophoresis with dual colour protein standards for 
determining the molecular mass and for monitoring the transfer. Proteins were stacked at 
80V for 30 mins and separated at 120 V. Electrotransfer at 350 A for 60-90 mins of a 
combination of gel, membrane and electrodes immersed in a transfer buffer enabled 
migration of proteins from the gel onto a pre-activated PVDF membrane (0.45 μM, Mini 
Trans-Blot Bio-Rad). The membrane were blocked with 5% non-fat milk (w/v) in TBS-T 
to reduce non-specific binding and incubated with the appropriate primary antibody over-
night at 4°C. Subsequently, they were washed thrice for five minutes with TBS-T to wash 
away weakly or unbound antibodies and incubated with the species specific secondary 
antibody conjugated to horseradish peroxidase for 1 hour at room temperature. Finally, 
the membranes were washed thoroughly with TBS-T and TBS and chemiluminescence 
(Luminata Forte) was used for band visualization in combination with ImageQuant LAS 
4000 system. Band intensity was quantified using ImageJ and β-actin was used for 
normalization.  
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              Table 11: SDS gel components 
 Separating 
gel (10%) 
Stacking 
gel (4%) 
1.5M Tris-HCl (pH 8.8) 2.5 ml - 
1.5M Tris-HCl (pH6.8) - 0.5 ml 
SDS (10%) 100 μl 40 μl 
APS (10%) 100 μl 40 μl 
Acrylamide (30%) 3.3 ml 0.67 ml 
TEMED  4 μl  4 μl 
Water  4 ml 2.7 ml 
Total 10 ml  4ml 
 
4.13 Flow Cytometry 
HUVECs (1x10
6
) were washed twice with FACS buffer and detached with 300 μl 
Accutase® cell detachment solutions. Cells were centrifuged at 1000 rpm for 5 minutes 
and the pellet was washed twice with FACS buffer followed by incubation with the 
appropriate antibodies (CD40 and VCAM-1) and their respective IgG controls for 30 
mins at 4°C. Unstained and untreated cells were used as controls.  Finally cells were 
washed with 1 ml FACS buffer, re-suspended in 300 μl FACS buffer and analyzed 
immediately. 10,000 cells were measured in every experiment which was performed on a 
BD FACSDiva® flow cytometer using BD FACSDiva version 6 software. Analyses were 
carried out in collaboration with Dr. Michael Weitnauer, Department of Medical 
Microbiology and Hygiene, Heidelberg University. 
      4.14 Coronary heart disease patient sample collection 
Blood samples were provided by Dr. Florian Leuschner (University Hospital Heidelberg, 
Antragsnummer: S-390/2011) and Dr. Thorsten Kessler (German Heart Centre, Munich, 
Antragsnummer: S-689/2015). Patients were diagnosed with CHD when blockage of at 
least one coronary artery by 25% was confirmed by coronary angiography. Additional 
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requirements for diagnosis were a lack of myocardial infarction, unstable angina and 
confounding chronic inflammatory conditions like rheumatoid arthritis and inflammatory 
bowel disease. The average age of the patients was 71.3±12.7. Age-matched control 
samples which had a mean age of 64±3, were provided by Dr. Maik Brune (University 
Hospital Heidelberg). 
4.15 Inflammatory arthritis patient sample collection 
Blood samples of RA and PsA patients were kindly provided by Prof. Dr. Hanns Marti-
Lorenz (University Hospital Heidelberg Antragsnummer: S-689/2015). Patients were 
diagnosed as per the 2010 Rheumatoid Arthritis Classification Criteria (Aletaha et al., 
2010). According to these criteria, definite RA is diagnosed when there is the presence of 
synovitis in at least one joint coupled with an inadequate explanation for its presence. 
Additionally, six out of ten possible points in a scoring system measuring 4 domains must 
be obtained. The four domains are: number and site of joints affected, serologic 
abnormality, elevated acute-phase response and symptom duration. The CASPAR 
classification criterion was used for PsA diagnosis (Taylor et al., 2006). To be classified 
as PsA positive, a patient must have inflammatory articular disease and score a minimum 
of 3 out of 5 points in the following domains: 1) evidence of psoriasis 2) psoriatic nail 
dystrophy 3) negative test result for rheumatoid factor 4) current of a history of dactylitis 
and 5) radiological evidence of juxta-articular new bone formation.  
4.16 Statistical analysis 
All data are represented as mean ± SEM with ‘n’ denoting biological replicates unless 
stated otherwise. To determine if the data followed Gaussian distribution the D’Agostino-
Pearson omnibus test was used. Differences between two groups (control vs stimulated) 
were determined using the unpaired Students t-test or Mann-Whitney U test (parametric 
vs non-parametric respectively). Variations between three or more groups (e.g., CC, CT 
and TT genotype endothelial cells) were computed by one-way ANOVA with Tukey’s 
post-hoc test. Data which was not normally distributed was analyzed by Kruskal-Wallis 
ANOVA test with Dunn’s multiple comparison. Mean differences between two 
independent variables (genotype and stimulation) were analyzed by two-way ANOVA 
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with Tukey’s post-hoc test. Hardy-Weinberg equilibrium for the -1C/T CD40 SNP was 
determined by Chi-square goodness of fit test with 1 degree of freedom and odds ratio by 
Fischer’s exact test. Additionally, the Grubb’s test was used to determine outliers. All 
data was analyzed by GraphPad® Prism 6 (Version 6.01) software. 
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      5 RESULTS 
5.1 Distribution of the -1C/T CD40 SNP in Baden-Württemberg 
To determine the distribution of the –1C/T SNP in the CD40 gene in the local population, 
470 genomic DNA samples isolated from collected umbilical cords from Heidelberg 
hospitals were subjected to polymerase chain reaction-restriction fragment length 
polymorphism analysis. Since the presence and distribution of single nucleotide 
polymorphisms varies depending on the ethnicity and race of the population being 
studied, DNA samples from the local region were analyzed to estimate allele frequency 
and genotype distribution. Genotyping efficiency was <95% and three distinct genotypes 
in Hardy-Weinberg equilibirum were present. The results showed a clear dominance of 
the C allele (Figure 6A) and of the homozygous C genotype (Figure 6B). 
 
 
Figure 6: The C allele is dominant in the local population. (A) Allele frequency and 
(B) genotype distribution of -1C/T SNP. Genotyping was performed by PCR-based RFLP 
analysis of genomic DNA isolated from umbilical cords of newborns; n=470. HWE 
(p>0.1)  
 
5.2 Effect of the -1C/T CD40 SNP on endothelial CD40 expression 
The -1C/T SNP is located in a strategic position surrounding the AUG initiation codon in 
the Kozak consensus sequence. Since the sequence neighboring the AUG initiation codon 
in an mRNA is a determinant of the efficiency of the protein translation machinery, we 
analyzed the impact of the -1C to T transition on CD40 expression in genotype stratified 
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primary HUVECs. Predictaby, the CD40 mRNA levels were comparable in all genotypes 
(Figure 7A). However, a genotype-dependent effect was clearly seen in intracellular and 
surface CD40 protein levels, measured by immunoblotting and flow cytometry, 
respectively (Figure 7B and C). Intracellularly, homozygous C genotype (CC) cells 
expressed twice as much protein than endothelial cells isolated from heterozygous (CT) 
or homozygous T genotype (TT) carriers (Figure 7B). This phenotypic difference was 
clearly more pronounced with respect to CD40 protein detected on the surface of the CC 
cells as compared to the CT or TT cells (Figure 7C). Collectively, cell surface expression 
levels on CC cells were 1.3- and 5.7-fold higher as compared to the CT and TT genotype 
cells, respectively. These measurements indicate an additive effect of the T allele with 
CD40 protein levels decreasing significantly in the presence of one T allele and further in 
the presence of two T alleles. 
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Figure 7: The -1C/T SNP affects endothelial CD40 protein expression. (A) 
Quantitative RT-PCR analysis of CD40 mRNA levels in CC, CT and TT genotypes. 
Crossing points were normalized to the housekeeping gene GAPDH. (B) Western blot 
analyses of CD40 protein normalized to β-actin as a loading control in whole cell lysates 
from HUVECs with different genotypes.**p<0.01 (C) Flow cytometry analyses of CD40 
cell surface protein abundance in HUVECs with different genotypes (10,000 cells were 
used per FACS measurement). Isotype control and unstained cells were analyzed to 
determine sensitivity of the staining protocol (D) Representative FACS histograms are 
depicted; *p<0.05; **p<0.01, n-numbers are denoted in brackets on the graph adjacent 
to the genotype. 
 
5.3 Effect of the -1C/T CD40 SNP on sCD40L-induced proinflammatory gene 
expression  
CD40 protein has a critical role in immunity and inflammation. Associated signaling is 
known to increase the expression of proinflammatory genes and adhesion molecules to 
facilitate the binding of monocytes and lymphocytes to the vascular endothelium. We 
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were interested to determine if the effect of the -1C/T SNP of the CD40 gene is limited to 
protein abundance or if there are also downstream consequences which take place by 
influencing sCD40L-induced signaling. To test if variation in CD40 protein abundance 
has an impact on proinflammatory gene expression in endothelial cells, expression of 
three proinflammatory mediators, VCAM-1, MCP-1, and the leuckocyte adhesion 
molecule E-selectin, were analyzed under three different proinflammatory conditions that 
are described in the following three sections. 
The following section presents data comparing gene expression in non-stimulated and 
sCD40L-stimulated HUVECs with and without genotype stratification. HUVECs were 
stimulated with sCD40L (200ng/ml) for 8 hours and 24 hours to measure changes in 
mRNA and protein expression respectively.  
 
5.3.1 Impact on CD40 cell surface abundance 
CD40 belongs to the TNFR superfamily in which signal transduction varies depending on 
whether the receptor remains on the cell surface or is internalized. Following ligation the 
CD40 receptor is rapidly internalized into early stage endosomes in a cholesterol-
dependent manner. The internalized protein is sequestered into vesicles with the capacity 
to phosphorylate Akt and lead to NF-kB activation (Chen et al., 2007). Therefore, it was 
not surprising to note an obvious and significant decrease in surface CD40 levels 24 
hours post-ligation with sCD40L (Figure 8A). Moreover, TT cells internalized CD40 to a 
greater extent (0.44-fold) than CT or TT (0.33-fold) cells (Figure 8B).  
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Figure 8: sCD40L induces genotype-dependent internalization of surface CD40. 
FACS analyses of CD40 cell surface protein appearance. MFI of 10,000 cells was 
analyzed. (A) sCD40L stimulation induces a significant decrease in surface CD40; 
n=17;**p<0.01 vs control. (B) The decrease was significant in CC and CT but not TT 
genotype cells; *p<0.05, n-numbers are denoted in brackets on the graph adjacent to the 
genotype. 
 
5.3.2 Impact on sCD40L-induced VCAM-1 expression 
The first read-out for measuring the effect of CD40-sCD40L-interaction on 
proinflammatory gene expression was VCAM-1. Exposure of HUVECs to sCD40L 
induced a 44-fold increase in VCAM-1 mRNA expression independent of the genotype 
(Figure 9A). Genotype-dependent effects were clearly observed with CC cells having the 
highest capacity to upregulate VCAM-1 (70-fold) compared to 15- and 6-fold 
upregulation in CT and TT genotype cells, respectively (Figure 9B). Exposure of 
HUVECs to sCD40L elicited a total 13-fold increase in surface VCAM-1 protein (Figure 
10A). The CC cells exhibited the highest upregulation (30-fold) compared to CT and TT 
genotype cells (6- and 8-fold, respectively). Similar to mRNA levels, the presence of one 
T allele was sufficient to diminish sCD40L-induced VCAM-1 protein upregulation 
significantly (Figure 10B). 
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Figure 9: sCD40L-induced VCAM-1 mRNA expression is affected by the -1C/T SNP 
of the CD40 gene. (A) Soluble CD40L induces a marked upregulation of VCAM-1 mRNA 
levels in all cells; n=16; **p<0.01 vs control. (B) The -1C/T genotype differentially 
affects this upregulation; *p<0.05, **p<0.01, n-numbers are denoted in brackets on the 
graph adjacent to the genotype. 
 
 
Figure 10: sCD40L-induced VCAM-1 protein expression is affected by -1C/T 
SNP. Flow cytometry analyses of VCAM-1 cell surface protein levels. MFI of 10,000 
cells was analyzed. (A) Genotype-independent upregulation of surface VCAM-1 protein; 
n=16;**p<0.01 vs control. (B) Genotype-dependent upregulation of surface VCAM-1 
protein; **p<0.01, n-numbers are denoted in brackets on the graph adjacent to the 
genotype. 
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5.3.3 Impact on sCD40L-induced MCP-1 expression 
The second gene analyzed as a read-out was MCP-1. Monocyte transmigration and 
differentiation into macrophages occurs along a MCP-1 gradient, underlying the key role 
of this chemotactic agent in immunity and inflammation (Randolph and Furie, 1995). 
Soluble CD40L induced a genotype-independent 13-fold increase in MCP-1 mRNA 
expression in HUVECs (Figure 11A). This increase was variable depending on the 
genotype with 18-fold upregulation of MCP-1 mRNA in CC genotype cells, 10-fold in 
CT and 8-fold in TT genotype cells (Figure 11B). Upregulation thus peaked in cells 
homozygous for the C allele and progressively decreased with addition of the T allele. 
Upregulation of MCP-1 protein followed a similar pattern. Exposure to sCD40L for 24 
hours elicited a genotype-independent increase in protein by 1.8-fold (Figure 11C). No 
significant differences were observed within the genotypes but the recorded increase was 
maximum in the CC genotype cells (2.3-fold) as compared to the CT (1.7-fold) and TT 
(1.1-fold) genotype cells (Figure 11D). 
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Figure 11: sCD40L-induced MCP-1 mRNA expression is affected by the -1C/T 
CD40 genotype. (A) Genotype-independent upregulation of MCP-1 mRNA; n=23,  
**p<0.01 vs control. (B) Genotype-dependent upregulation of MCP-1 mRNA; *p<0.05, 
**p<0.01. ELISA based quantitation of MCP-1 in HUVEC supernatants. (C) Genotype-
independent upregulation of MCP-1 protein; n=18; **p<0.01 vs control. (D) Genotype-
dependent upregulation of MCP-1 protein, n-numbers are denoted in brackets on the 
graph adjacent to the genotype. 
 
5.3.4 Impact on sCD40L-induced E-selectin expression 
E-selectin facilitates leukocyte rolling to enable leukocyte recruitment and extravasation. 
Enhanced leukocyte adhesion to HUVECs is dependent upon CD40L-induced E-selectin 
expression (Urban et al., 2011). Soluble CD40L induced a striking, genotype-independent 
230-fold upregulation in E-selectin mRNA (Figure 12A) which was even higher (335-
fold) in CC genotype cells but lower in CT (120-fold) or TT (180-fold) genotype cells 
(Figure 12B). Soluble CD40L induced a genotype-independent 1.6-fold upregulation in 
E-selectin protein released into the cell culture supernatant (Figure 12C) which was 
comparable in all genotypes (Figure 12D). 
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Figure 12: Impact of the -1C/T CD40 genotype on E-selectin expression. (A) 
Genotype-independent upregulation of E-selectin mRNAs; n=14; **p<0.01 vs control. 
(B) Genotype-dependent upregulation of E-selectin mRNA. (C) Genotype–independent 
upregulation of E-selectin protein; n=17; **p<0.01 vs control. (D) Genotype-dependent 
upregulation of E-selectin protein, n-numbers are denoted in brackets on the graph 
adjacent to the genotype. 
 
5.4 Functional impact of the -1C/T CD40 SNP on monocyte adhesion to endothelial 
cells 
Taken together, the aforementioned results indicate that the degree of sCD40L-induced 
proinflammatory gene expression in endothelial cells is dependent on the genotype for 
the -1C/T SNP of the CD40 gene. The functional consequences of this effect were 
analyzed by employing a monocyte adhesion assay. Leukocyte adhesion to the vascular 
endothelium is an early event in atherosclerosis. It is initiated by leukocyte rolling, 
mediated by E-selectin while stable adhesion and leukocyte extravasation through the 
endothelium is facilitated by VCAM-1 and ICAM-1 (Hogg and Landis, 1993; Luscinskas 
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et al. 1996). Since the C allele of the -1C/T SNP was found to be associated with higher 
VCAM-1 expression post-sCD40L stimulation, its functional consequence was analyzed 
by quantifying the number of monocytes that adhered to sCD40L pre-stimulated 
endothelial cells with different -1C/T genotypes. Independent of the genotype of the 
endothelial cells, there was a 6-fold increase in monocyte adhesion post-stimulation with 
sCD40L (Figure 13A). Compared with non-stimulated cells the maximum adhesion 
occurred in CC genotype cells (12-fold) but was reduced to 3-fold by the presence of one 
T allele (CT and TT genotype cells) (Figure 13B). 
 
 
Figure 13: SolubleCD40L-induced monocyte attachment to the endothelial 
monolayer is highest in CC genotype cells. Quantification of fluorescently labelled 
(green) THP-1 cells adhering to HUVECs stimulated for 2 hours with sCD40L. (A) 
Genotype independent adhesion of THP-1 cells; n=17, **p<0.01 vs control. (B) 
Genotype-dependent adhesion of THP-1 cells;*p<0.05, n-numbers are denoted in 
brackets on the graph adjacent to the genotype. 
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5.5 Impact of the -1C/T CD40 SNP on cytokine-activated and sCD40L-stimulated 
endothelial cells 
During inflammatory conditions sCD40L is released from platelets while at the same 
time cytokines are released from Th1 cells and macrophages. Consequently, in an 
inflammatory context endothelial cells are simultaneously acted upon by CD40L and 
cytokines like TNF-α and IFN-γ which act synergistically to upregulate CD40 (Henn et 
al., 1998 and 200; Wagner et al., 2002; Yellin et al., 1995). Therefore, we investigated 
the impact of the -1C/T CD40 SNP on sCD40L-induced signaling in a proinflammatory 
context which would include cytokines. Such conditions were simulated in vitro by 
exposing cytokine-primed HUVECs to sCD40L. Their combined effect on CD40 protein 
expression was examined. Additionally, as read-outs for CD40-dependent intracellular 
signaling, the same panel of genes as in section 5.2 through 5.4 was analyzed and the 
results are presented in the following section. Stimulation details are described in the 
Materials and Methods section. 
5.5.1 Impact on CD40 gene expression 
Stimulation induced a significant increase in CD40 at the mRNA (2.9-fold) and protein 
(2-fold) level (Figure 14A and B). In genotype stratified cells, upregulation of CD40 
mRNA was significantly higher in TT genotype cells (Figure 15A). This effect was not 
translated to the protein level where all genotypes showed a similar upregulation of total 
CD40 protein (Figure 15C). However, basal levels of CD40 protein on the cell surface 
were significantly different between the three genotypes (Figure 15B), and interestingly 
this difference remained the same following cytokine-priming and sCD40L stimulation 
with surface CD40 protein being highest in CC genotype cells followed by the CT and 
the TT genotype (Figure 15B).  
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Figure 14: CD40 gene expression is upregulated under proinflammatory conditions. 
(A) CD40 mRNA and (B) protein expression is induced by sCD40L stimulation of primed 
cells of all -1C/T genotypes of the CD40 gene. (A) qRT-PCR of CD40 mRNA expression; 
n=23, **p<0.01 vs control. (B) FACS analysis of CD40 stained cells. MFI of ten 
thousand cells was analyzed. Representative histograms with unstained controls are 
depicted; n=40, **p<0.01 vs control. 
 
 
Figure 15: Impact of the -1C/T SNP on CD40 surface protein under 
proinflammatory conditions. (A) Genotype-dependent upregulation of CD40 mRNA; 
*p<0.05. (B&C) Genotype-dependent upregulation of CD40 protein expressed as MFI of 
all cells (B) and fold increase relative to control (C)*p<0.05, **p<0.01, n-numbers are 
denoted in brackets adjacent to the genotype.  
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5.5.2 Impact on VCAM-1 gene expression 
Under these simulated proinflammatory conditions VCAM-1 mRNA expression 
increased up to 75-fold independent of the genotype (Figure 16A). The presence of one 
T allele was sufficient to halve this effect which not reduced further in TT genotype cells 
(Figure 16B).  Independent of the genotype there was also a marked 48-fold increase in 
VCAM-1 protein (Figure 17A) that rose to 140-fold in CC genotype cells, 120-fold in 
CT genotype cells and was non-significantly less in TT genotype cells (40-fold) (Figure 
17B). Total VCAM-1 protein abundance post-stimulation was 3-fold higher in CC 
genotype cells as compared to the TT genotype (Figure 17C). 
 
 
Figure 16: CC genotype is associated with higher VCAM-1 mRNA expression. (A) 
Genotype independent up-regulation of VCAM-1 mRNA after cytokine priming and 
sCD40L stimulation; n=16; **p<0.01 vs control. (B) Genotype-dependent up-regulation 
of VCAM-1;**p<0.01, n-numbers are denoted in brackets adjacent to the genotype.  
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Figure 17: s. Flow cytometry analyses of VCAM-1 cell surface protein upregulated after 
cytokine priming of sCD40L stimulation.(A) Genotype-independent upregulation of 
VCAM-1 protein; n=10, **p<0.01 vs control. (B & C) Genotype-dependent upregulation 
of VCAM-1 protein expressed as MFI of all cells (B) and fold increase relative to control 
(C), n-numbers are denoted in brackets adjacent to the genotype. MFI of 10,000 cells 
analyzed per FACS measurement.   
 
5.5.3 Impact on MCP-1 gene expression 
Following stimulation with cytokines and sCD40L, the MCP-1 mRNA expression 
increased up to 38-fold independent of the genotype (Figure 18A). The presence 
of the T allele halved this effect which was further reduced when the T allele was 
homozygous (Figure 18B). MCP-1 protein quantified in the cell supernatants 
increased up to 1.4-fold independent of the genotype (Figure 18C) with the 
maximum increase (2-fold) in the CC genotype cells (Figure 18D). 
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Figure 18: sCD40L-induced MCP-1 mRNA expression is affected by the -1C/T 
CD40 genotype. (A) Genotype-independent upregulation of MCP-1 mRNA; n=20, 
**p<0.01 vs control. (B) Genotype-dependent upregulation of MCP-1 mRNA; **p<0.01. 
(C&D) ELISA based quantitation of MCP-1 in HUVEC supernatants. (C) Genotype-
independent upregulation of MCP-1 protein; n=12; **p<0.01 vs control. (D) Genotype-
dependent upregulation of MCP-1 protein, n-numbers are denoted in brackets on the 
graph adjacent to the genotype. 
 
5.5.4 Impact on E-selectin gene expression 
Finally, soluble CD40L-induced E-selectin expression was compared in cytokine-primed 
HUVECs derived from homozygous or heterozygous carriers of the -1C/T SNP of the 
CD40 gene. E-selectin mRNA expression exhibited a strong upregulation (354-fold) 
independent of the genotype (Figure 19A) which was comparable in the CC (594-fold) 
and CT (414-fold) genotype cells but was diminished to 54-fold in the TT genotype cells 
(Figure 19B). Independent of the genotype there was an 11.5-fold increase in the E-
selectin protein released into the cell culture supernatants (Figure 19C) which was even 
higher (15-fold) in the CC genotype cells but lowed in the CT (11-fold) and TT (8-fold) 
genotype cells (Figure 19D).   
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Figure 19: Impact of the -1C/T CD40 genotype on E-selectin expression. (A) 
Genotype-independent upregulation of E-selectin mRNA; n=12; **p<0.01 vs control. (B) 
Genotype-dependent upregulation of E-selectin mRNA;**p<0.01. (C) Genotype–
independent upregulation of E-selectin protein; n=14; **p<0.01 vs control. (D) 
Genotype dependent upregulation of E-selectin protein; **p<0.01, n-numbers are 
denoted in brackets on the graph adjacent to the genotype.  
 
The -1C/T SNP of the CD40 gene affects the baseline CD40 abundance on the 
endothelial cell surface. This phenotype was maintained following cytokine upregulation 
of CD40 and sCD40L stimulation. Against this background, a genotype-dependent 
difference in CD40-mediated signaling measured via monitoring changes in the 
expression of proinflammatory endothelial gene products was also observed. Altogether, 
the aforementioned results indicate that the endothelial cell response to proinflammatory 
stimuli following sensitization to sCD40L is dependent on the genotype of the -1C/T 
SNP of the CD40 gene and is highest in cells which are homozygous for the C allele.  
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5.6 Role of the -1C/T CD40 SNP in predisposing HUVECs towards an inflammatory 
phenotype in the absence of recombinant sCD40L 
As shown before, the proinflammatory gene products MCP-1, VCAM-1 and E-selectin 
were expressed in endothelial cells after cytokine (TNF-α, IFN-γ) priming followed by 
exposure to sCD40L. As summarized in table 12, this combined stimulation induced an 
approximately 2-fold greater increase in VCAM-1, MCP-1 and E-selectin mRNA 
expression as compared to sCD40L stimulation alone (for detailed analysis please refer 
to sections 5.3-5.5), presumably through enhanced cytokine-induced CD40 receptor 
expression which augmented CD40 receptor-mediated downstream signaling. It is also 
possible that the -1C/T SNP influences the proinflammatory response of endothelial cells 
to cytokines in the absence of sCD40L. To test this idea, genotype-stratified HUVECs 
were stimulated in vitro only by using the combination of TNF-α and IFN-γ.  
Table 12: Effects of cytokine priming in combination with sCD40L stimulation as 
compared to sCD40L stimulation alone on proinflammatory gene expression (mRNA) 
in the cultured HUVECs independent of the -1C/T SNP of the CD40 gene. qRT-PCR 
measurement of mRNA levels of VCAM-1, MCP-1 and E-selectin. *p<0.05. 
 
 
 
 
 
5.6.1 Impact on CD40 gene expression 
Stimulation with cytokines (TNF-α, IFN-γ) in the absence of sCD40L induced the highest 
CD40 protein increase independent of the -1C/T SNP of the CD40 gene, as compared to 
stimulation with sCD40L alone or in combination with cytokines (Figure 22A). As 
mentioned before, exposure to sCD40L induces internalization of the CD40 receptor 
leading to a decrease in the CD40 protein detectable on the cell surface, while 
proinflammatory cytokines such as TNF-α and IFN-γ induce its release (for greater detail, 
please refer to 5.3.1 and 5.5.1). Consequently, cytokine stimulation in the absence of 
sCD40L induced a higher (3.5-fold) increase in CD40 protein expression, as compared to 
 VCAM-1  
(n=16-18) 
MCP-1 
(n=20-23) 
E-selectin 
(n=12-14) 
sCD40L 
 
44.0 ± 9.4 13.4 ±1.3 229.8±41.9 
TNF-α+IFN-γ+sCD40L 
 
72.6 ± 14.0 37.7±5.0 450.3±98.0 
Fold increase 
 
1.7 2.8** 2.0* 
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the increase post-stimulation (2-fold) with a combination of cytokines and sCD40L 
(Figure 22A). Following the same pattern as depicted in 5.5.1, the highest CD40 surface 
protein expression after cytokine priming was observed in the CC genotype, followed by 
the CT and the TT genotype (Figure 22B). 
       
Figure 20: Cytokine treatment induces CD40 expression in a manner dependent on 
the genotype of the -1C/T SNP of the CD40 gene. (A) CD40 protein expression 
independent of the -1C/T SNP of the CD40 gene following stimulation with sCD40L, a 
combination of sCD40L and cytokines (TNF-α and IFN-γ) and cytokines without sCD40L, 
n=17, 23, 23 for sCD40L, cytokines and combination of cytokines and sCD40L 
respectively;**p<0.01. (B) Genotype-dependent upregulation of CD40 protein following 
exposure to cytokines;**p<0.01, n-numbers denoted in brackets adjacent to the genotype. 
 
 5.6.2 Impact on VCAM-1 expression 
Exposure of HUVEC to TNF-α and IFN-γ induced a highly significant, genotype-
independent 34-fold increase in VCAM-1 mRNA (Figure 21A) which was even higher 
(65-fold) in the CC genotype cells but reduced to 20-fold in the CT genotype cells and 9-
fold in the TT genotype cells (Figure 21B). Independent of the genotype there was a 
significant (26-fold) increase in VCAM-1 protein (Figure 22A) that was highest in the 
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CC genotype cells (69-fold) compared to 42-fold in the CT genotype cells and 33-fold in 
the TT genotype cells (Figure 22 B).   
 
Figure 21: Cytokine-induced VCAM-1 mRNA expression is affected by the -1C/T 
CD40 genotype (A) Genotype-independent upregulation of VCAM-1 mRNA; n=16, 
**p<0.01 vs control. (B) Genotype-dependent upregulation of VCAM-1 mRNA; 
**p<0.01, n-numbers are denoted in brackets on the graph adjacent to the genotype.  
 
 
Figure 22: Impact on cytokine-induced VCAM-1 protein expression. Flow cytometry 
analyses of VCAM-1 cell surface protein levels. MFI of 10,000 cells was analyzed. (A) 
Genotype-independent upregulation of surface VCAM-1 protein; n=11; **p<0.01 vs 
control. (B &C) Genotype-independent upregulation of surface VCAM-1 protein 
expressed as total MFI (B) and folds relative to controls (C); n-numbers are denoted in 
brackets on the graph adjacent to the genotype.  
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5.6.3 Impact on MCP-1 expression 
Cytokine exposure induced a genotype-independent 24-fold increase in MCP-1 mRNA 
(Figure 23A). The increase in the homozygous C genotype cells was 36-fold, which was 
significantly greater than the 17- and 5-fold increases observed in the heterozygous and 
homozygous T genotype cells (Figure 23B). MCP-1 protein quantified in the cell 
supernatant showed a genotype-independent 1.5-fold increase (Figure 23C). No 
significant differences were observed within the genotypes however an increase could be 
seen in only the CC genotype cells while the CT and TT genotype cells did not respond 
to the stimulation (Figure 23D). 
 
Figure 23: Impact of -1C/T genotype on cytokine induced MCP-1 gene expression. 
(A) Genotype-independent upregulation of MC-1 mRNA post-cytokine stimulation; n=20; 
**p<0.01 vs control. (B) Genotype-dependent upregulation of MCP-1 mRNA; **p<0.01, 
n-numbers are denoted in brackets adjacent to the genotype. (C) Genotype-independent 
upregulation of MCP-1 protein quantified by ELISA; n=20, **p<0.01 vs control. (D) 
Genotype-dependent upregulation of MCP-1 protein, n-numbers are denoted in brackets 
on the graph adjacent to the genotype. 
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5.6.4 Impact on E-selectin expression 
Exposure to cytokines induced a genotype-independent 94-fold increase in E-selectin 
mRNA (Figure 24A). The presence of two T alleles dramatically reduced this effect from 
a 154 and 125-fold induction in the CC and CT genotype cells to only 1.5-fold in the TT 
genotype cells (Figure 24B). Independent of the genotype, there was a 10-fold increase 
in E-selectin protein post-cytokine stimulation (Figure 24C) which was highest in the CC 
genotype cells (16-fold) but was markedly reduced in the TT genotype (4-fold) cells 
(Figure 29D). 
 
Figure 24: Impact of -1C/T genotype of the CD40 gene on cytokine induced E-selectin 
gene expression. (A) Genotype-independent upregulation of E-selectin mRNA post-
cytokine stimulation; n=12; **p<0.01 vs control. (B) Genotype-dependent upregulation 
of E-selectin mRNA; **p<0.01, n-numbers are denoted in brackets adjacent to the 
genotype. (C) Genotype-independent upregulation of E-selectin protein quantified by 
ELISA; n=14, **p<0.01 vs control. (D) Genotype-dependent upregulation of E-selectin 
protein, *p<0.05; **p<0.01, n-numbers are denoted in brackets on the graph adjacent to 
the genotype. 
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5.7 CD40 isoforms in endothelial cells 
Regulation of mouse and human CD40 expression through the generation of alternative 
splice variants has been shown previously (Tone et al., 2000; Eshel et al., 2008). The 
major alternative isoform in which exon 6 is spliced out is known as isoform 2 or sCD40-
6. This soluble receptor isoform has been reported to reduce expression of the full length 
signaling competent CD40 in a human B lymphocyte cell line by acting as a decoy 
receptor (Eshel et al., 2008). However, there is no information regarding the presence or 
function of CD40 isoforms in human endothelial cells. Therefore we were interested to 
determine if sCD40-6 is conserved in human endothelial cells, if it is affected by 
proinflammatory stimuli, and if the -1C/T SNP of the CD40 gene is associated with 
changes not only in full-length CD40 but also sCD40-6. 
5.7.1 Expression of inducible sCD40-6 in human endothelial cells 
The presence of three additional isoforms could be detected by running the products of a 
semi-quantitative PCR on an agarose gel (Figure 25A). sCD40-6 lacks exon 6, sCD40-5 
is missing exon 5 and sCD40-5+6 is missing both of them. Of these isoforms only 
sCD40-6 was studied further since this isoform is known to retain three cysteine rich 
domains and the capacity to bind CD40L, therefore it can act as a soluble decoy receptor 
for CD40L. Cytokine priming with and without additional sCD40L stimulation 
significantly increased mRNA expression of sCD40-6 (Figure 25B). To investigate if 
there is an association between the -1C/T SNP of the CD40 gene and sCD40-6 levels 
under proinflammatory conditions genotype-stratified endothelial cells were analyzed, 
however all genotypes upregulated sCD40-6 in a comparable manner (Figure 25C). 
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Figure 25: Endothelial cells express cytokine-inducible CD40 isoforms at mRNA 
level. (A) Representative image of PCR products separated on a 2% agarose gel. (B) 
qRT-PCR of mRNA isolated from HUVECs stimulated with cytokines ± sCD40L; 
*p<0.05; **p<0.01 vs control, n=12. (C) No effect of -1C/T CD40 genotype on cytokine 
inducible sCD40-6 mRNA expression, n-numbers are indicated on the graph adjacent to 
the genotype. 
 
      5.7.2 Association of soluble CD40 protein with the -1C/T SNP of the CD40 gene 
Soluble CD40 proteins can be generated by alternative splicing or TNF- converting 
enyzme (TACE)-mediated cleavage of transmembrance CD40. Soluble CD40 levels have 
been shown to be elevated in the plasma of patients in a number of pathological 
conditions (refer to section 2.2.4). To elucidate if the -1C/T SNP of the CD40 gene 
correlates with altered sCD40 protein levels, gentoype-stratified HUVECs were analyzed 
post-sCD40L stimulation (Figure 26). A trend indicating an increase in sCD40 protein 
expression (p=0.087) following 24-hour stimulation with sCD40L was observed (Figure 
26A) with no significant effect of the -1C/T SNP of the CD40 gene obtained (Figure 
26B).  
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Figure 26: Effect of sCD40L-induction on endothelial sCD40 protein 
expression. (A) ELISA based quantitation of soluble CD40 protein released into 
HUEVC supernatants 24 hour post-sCD40L stimulation independent of -1C/T CD40 
genotype, n=10. (B) Genotype-dependent effect of sCD40L on sCD40 release, n-numbers 
are denoted in brackets on the graph adjacent to the genotype.  
 
5.8 Association of the -1C/T SNP of the CD40 gene with coronary heart disease 
Endothelial dysfunction is accepted as an independent risk factor for vascular disease and 
its contribution to atherosclerotic disease development and progression is undisputed. 
Data presented in sections 5.2 to 5.6 indicate that the C allele of -1C/T SNP of the CD40 
gene acts as a gain of function allele (in comparison to the T allele) and confers an 
activated phenotype to the CC genotype endothelial cells.  
To determine if the -1C/T SNP of the CD40 gene could be a risk factor for coronary heart 
disease (CHD) via increasing CD40 abundance on endothelial cells and therefore 
imparting the risk of enhanced adhesion molecule and chemokine expression, an 
association study was carried out. DNA isolated from the blood of 243 patients with 
coronary heart disease, diagnosed by coronary angiography, was genotyped. Age-
matched controls (76) were also genotyped. The sample size of the umbilical vein cohort 
was higher than the age-matched control group and the genotype distribution as well as 
the allele frequency of these two groups was highly comparable (Figure 27), hence the 
umbilical vein group was used as a reference control cohort for computing  odds ratios 
(table 13).  
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Figure 27: The -1C/T SNP of the CD40 gene has comparable genotype distribution 
and allele frequency in non-diseased and age-matched control groups. (A) Genotype 
distribution and (B) allele frequency of the non-diseased control group, n=470. (C) 
Genotype distribution and (D) allele frequency of age-matched controls, n=76. Values 
expressed as percentages. 
 
Both control populations were in Hardy-Weinberg equilibrium therefore an allelic 
association test was used for comparison. A significant difference in the C and T allele 
frequency between control and CHD cohorts was observed (table 13). Carriers of the 
enhanced function C allele of the -1C/T SNP of the CD40 gene exhibited an elevated 
odds ratio for CHD (75.9% vs 68.5% cases vs controls,  OR=1.43; 95% CI=1.13-1.86, 
p=0.0038). Therefore the C allele was found to be associated with a 1.4 times increased 
risk of CHD compared with the T allele. To analyze the association of CHD with the 
genotypes of this SNP, genotypic odds ratio were computed. Genotypic analysis (CC vs 
TT, cases vs controls) showed a significant association of the CC genotype  with CHD 
(OR=2.38; 95% CI= 1.28-4.42, p=0.0056). Taking the CT genotype into account, the 
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recessive model of penetrance was analyzed. According to this model, two copies of the 
C allele  would be required to increase the risk of disease (Clarke et al., 2011). 
Comparison of the TT genotype vs combined CC and CT genotypes in cases and control 
groups revealed an association of the TT genotype with decreased risk of CHD 
(OR=0.48; 95% CI=0.26-0.89, p=0.02). Altogether, these results confirm an association 
of the C allele and the CC genotype with susceptibility to CHD (table 13).    
Table 13: Association of the -1C/T SNP of the CD40 gene with susceptibility to CHD 
The distribution in total n numbers and percentages of the CC, CT and TT genotypes in 
coronary heart disease patients, controls (DNA from umbilical veins) and age-matched 
controls. N indicates number of subjects; ref: reference; CI, confidence interval; ns, non-
significant. Odds ratio computed by Fischer’s exact test. 
 
Allele Controls 
n=470 
CHD 
patients 
n=243 
Odds ratio 
(95% CI) 
P 
value 
C 644 (68.5%) 369 (75.9%) Reference  
T 296 (31.5%) 117 (24.1%) 1.43 (1.13-1.86) 0.038 
Genotype 
CC 228 (48.5%) 140 (57.6%) _  
CT 188 (40.0%) 89 (36.6%) _  
TT 54 (11.4%) 14 (5.7%) CC vs TT 
2.38 (1.28-4.42) 
0.02 
Recessive model  
TT 54 (11.4%) 14 (5.7%) 0.48 (0.26-0.89) 0.02 
CC+CT 416 (88.5%) 229 (94.2%) 
 
5.8.1 Association between sCD40 levels and -1C/T CD40 SNP in coronary heart 
disease 
Soluble CD40 can act as a negative regulator of CD40L-induced signaling. However 
there is no information regarding sCD40 levels in a CHD context and if it is affected by 
the -1C/T SNP genotype. To investigate this, the sCD40 levels in CHD patients’ plasma 
was quantified after genotype stratification. Analysis showed that the CC genotype was 
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associated with 1.5- and 2-fold higher sCD40 protein levels compared to the CT and TT 
genotype, respectively (Figure 28). 
 
Figure 28: Association between sCD40 serum levels and the -1C/T  SNP of the CD40 
gene in patients with CHD. Genotype-dependent release of sCD40 in CHD patients; 
**p<0.01, n-numbers are denoted adjacent to the genotypes .  
 
5.9 Association analysis of the -1C/T SNP of the CD40 gene with inflammatory 
arthritic diseases 
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory diseases 
associated with increased risk of cardiovascular morbidity and mortality. The CD40 locus 
has been shown by genome wide association studies to be implicated in RA pathogenesis  
(Raychaudhri et al., 2008). Therefore, the -1C/T SNP of the CD40 gene was also 
analyzed in patients with RA and PsA to determine its distribution and to confirm 
whether the C allele is a risk factor not only for CHD but also other chonic inflammatory 
conditions. Comparison of the allele frequencies of RA and Controls(umbilical vein 
DNA) did not show a significant difference however the C allele was  significantly 
associated with PsA (OR=1.93% CI: 1.20-3.11, p=0.005,table 14).  
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Table 14: The -1C/T SNP of the CD40 gene and Inflammatory arthritis risk. 
The Distribution in total n numbers and percentages of the CC, CT and TT genotypes in 
rheumatoid arthritis patients, controls (DNA from umbilical veins) and psoriatic arthritis 
patients. N indicates number of subjects; ref: reference; CI; confidence interval. Odds 
ratio (OR) computed by Fischer’s exact test 
 
Allele RA patients 
n=122 
Controls 
n=470 
PsA 
patients 
n=60 
C 179 (73.3%) 644 (68.5%) 97 (80.8%) 
T 65 (26.63%) 296 (31.5%) 23 (19.1) 
OR 
(95% CI) 
ns Reference 1.93 
(1.20-3.11) 
P value - - 0.0058 
CC 70 (57.3%) 228 (48.51%) 38 (63.3%) 
CT 39 (31.9%) 188 (40%) 21 (35.0%) 
TT 13 (10.7%) 54 (11.48%)  1 ( 1.7%) 
. 
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6. Discussion 
CD40 and its ligand represent an important co-stimulatory pathway with a wide 
expression profile. Since CD40-CD40L co-stimulation regulates both adaptive and innate 
immunity, changes in expression and/or function of these co-stimulatory molecules 
would have pathophysiological relevance. The C allele of a commonly occurring bi-
allelic SNP in the 5’ UTR of the CD40 gene has been described as a risk factor for a 
variety of auto-immune and inflammatory diseases (Jacobson et al., 2005; Tanizawa et al., 
2011; Tomer et al., 2002). While this SNP has been well studied, particularly in East 
Asian and Turkish populations (Inal et al., 2015; Yun et al., 2014), there are no reports 
which focus specifically on a CHD risk in a German subset. Therefore, in our study we 
investigated the effect of this common SNP in the local population, to acquire 
representative data on the importance of this SNP in the primarily Caucasian population 
of Northern Baden-Württemberg. 
6.1 The C allele is dominant in the local population 
SNPs are the most common type of genetic variation and they form the basis of human 
diversity. The most extensive and up-to-date information regarding human genetic 
variation is catalogued by the 1000 Genomes Project, which characterized 84.7 million 
SNPs in 26 populations (The 1000 Genomes Project Consortium, 2015). In this project, 
the European population is represented by the British, Finnish, Iberian Spanish, and 
Tuscan Italians, while Northern and Western Europe is represented by Utah residents 
with corresponding ancestry. The database reports a combined minor allele frequency 
(MAF) for the -1C/T SNP of the CD40 gene as 23% (T allele).  
However, ethnic differences play an important role in SNP presence and distribution. It is 
estimated that 85% of all SNPs are common in every human population while 15% are 
limited to certain geographical regions (Barbujani et al., 1997). For example, a SNP in 
the gene encoding the blood clotting cofactor protein S (Rs138925964) which is almost 
missing in the European population is significantly present in an African-descent group 
(Huang et al., 2015). 
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Analysis of the global distribution of the allele and genotype frequency of the -1C/T SNP 
of the CD40 gene also exhibits a clear geographical gradient (Figure 29). While the 
lowest MAF is present in the African (3%) and the highest in the East Asian populations 
(43%), it is comparable in the European and South Asian populations (26 and 27% 
respectively). In addition to population specificity, ethnic variability in allele and 
genotype frequency is not rare. One example is a C to T transition in the 
methylenetetrahydrofolate reductase (MTHFR) gene (Frosst et al., 1995). The 
distribution of the TT genotype ranges from 10-33% in the European, Asian and 
American populations, but is only 0-3% in the African populations (Wilcken et al., 2003).  
 
Figure 29: Global allele frequencies of the -1C/T SNP of the CD40 gene from the 
1000 Genomes Project. AFR, AMR, EAS, EUR and SAS refer to African, American, 
East-Asian, European and South-Asian populations, respectively 
In view of the importance of ethnic groups in SNP studies and the geographical gradient 
reported regarding the -1C/T SNP of the CD40 gene, we investigated its distribution in 
the local region of Northern Baden-Württemberg, Germany. DNA extracted from 470 
umbilical cords showed a MAF of 31% with genotype distribution of 49, 40 and 11% for 
the CC, CT, and TT genotypes, respectively (cf. Figure 6). This distribution follows the 
Hardy-Weinberg equilibrium, and the CC and CT percentages are comparable to the 
reported European distribution of 52 and 44%, respectively (1000 Genomes Project, 
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2015). However, the observed MAF was somewhat higher as the MAF (26%) reported by 
the 1000 Genomes Project consortium. There are certain possibilities for the discrepancy. 
Firstly, since 14% of the population in Heidelberg is from ancestry other than German 
and we do not have access to the ethnic heritage of our samples, it is not possible to rule 
out some population mixing. Additionally, as mentioned above, the 1000 Genomes 
Project does not include German samples but refers to a general Northern and Western 
European population which migrated to Utah, USA. It is possible that the Utah 
population does not properly reflect the European population and in particular the 
primarily Caucasian population of Northern Baden-Württemberg. Therefore it is possible 
that in Germany, the MAF of the -1C/T SNP of the CD40 gene is higher than in a 
combined Northern and Western European population.  
6.2 The -1C/T SNP of the CD40 gene is a regulator of endothelial cell CD40 protein  
Gene expression is a heritable, quantifiable and complex trait that is controlled by genetic, 
epigenetic and environmental factors (Cheung et al., 2005; Petronis, 2006). Gene 
transcription and translation are intricate and sophisticated mechanisms which require 
stringent control at multiple levels, including the initiation of translation. In eukaryotes, 
up to 12 different factors are known to influence this process and enable interaction of the 
methionyl-initiator tRNA with the AUG initiating codon in the P subunit of a ribosome 
(Heryshey and Merrick, 2000). The context in which the AUG codon is placed is known 
as the Kozak consensus and it is a strong determinant of the rate of translation initiation. 
The strongest sequence is one that contains a guanine at position +4 and an adenine at 
position -3. Presence of a cytosine at positions -1 and -2 also contributes to the overall 
strength of the Kozak sequence (Kozak 1984 and 1986). 
The -1C/T SNP of the CD40 gene is a cytosine to thymine transition in the Kozak 
sequence. As mentioned above, the presence of cytosine at position -1 enables the Kozak 
sequence to resemble the ideal sequence. Since the presence of the thymine nucleotide 
results in a disruption in this location, we hypothesized that there would be an effect on 
CD40 protein translation. As discussed in the introduction, CD40-CD40L interactions 
confer a pro-inflammatory phenotype to endothelial cells hence changes in gene 
expression in these cells could have significant pathophysiological consequences. Hence 
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the impact of this SNP on endothelial cell expression of pro-inflammatory gene products 
was evaluated. In resting HUVECs intracellular CD40 protein content and surface 
receptor density were both significantly higher in CC genotype cells than in CT or TT 
genotype cells. Interestingly, we observed a seemingly additive effect of the T allele 
regarding surface CD40 abundance, with an even greater decline in TT as compared to 
CT genotype cells. As expected, there were no differences in CD40 mRNA levels 
suggesting little influence of this SNP on transcription and stability of the CD40-
encoding mRNA. Our results correspond to other studies regarding the -1C/T SNP of the 
CD40 gene which consistently correlate the disrupted Kozak sequence with lower CD40 
protein levels. An in vitro study with transfected fibroblasts showed about 30% more 
CD40 protein in the C allele as compared to the T allele transfectants (Jacobson et al., 
2005). Functional studies using B lymphocytes (Park et al., 2007), dendritic cells 
(Skibola et al., 2008) and platelets (Yan et al., 2010) have also demonstrated increased 
CD40 protein in the presence of the C allele. Similarly, we detected up to 5.6-fold higher 
protein expression on the cell surface of endothelial cells with the CC genotype compared 
to the TT genotype. 
Kozak sequence SNP’ are also relevant in other genes. For instance, a G to C transition at 
the -6 position in the β-globin gene is associated with increased risk of thalassemia 
intermedia by decreased efficiency of translation of the β-globin chain (Angioletti et al., 
2004). Since the beta-globin protein is a subunit of hemoglobin, alteration in its protein 
levels would have clinical significance in blood-related disorders such as thalassemia. A  
-5C/T SNP in the glycoprotein Ib- gene (-5C/T) is an independent risk factor for 
ischemic stroke (Baker et al., 2001) via influencing plasma membrane levels of the 
platelet GP Ib-clotting factor IX-clotting factor V complex on platelets and transfected 
cells (Afshar-Kharghan et al., 1999).  
6.3 Correlation of increased CD40 surface content with stronger signal transduction 
CD40 ligation in endothelial cells has a similar effect as the pro-inflammatory cytokine 
TNF-α, which is characterized by increased expression of chemokines, cytokines and 
adhesion molecules. Consequently, there is increased leukocyte recruitment, adhesion 
and rolling, which are essential steps in leukocyte extravasation (Hollebaugh et al., 1995; 
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Yellin et al., 1995). We could demonstrate a clear impact of the -1C/T SNP of the CD40 
gene on CD40 protein abundance, namely on the endothelial cell surface which expresses 
low levels of CD40 protein under basal conditions (Wagner et al., 2011). It is interesting 
to note that even under this condition the difference in the protein expression of the 
genotypes of this SNP was detectable. Thus, we next analyzed functional activation of 
the receptor by using its recombinant soluble ligand. As read-outs for CD40 downstream 
signaling, the expression of MCP-1, VCAM-1 and E-selectin was compared in CC, CT 
and TT genotype endothelial cells. These gene products were selected since they are well 
known to be upregulated by CD40 ligation in endothelial cells and all considered to be 
pivotal for the onset and development of atherosclerosis (Pluvinet et al., 2008).  
Compared to non-stimulated cells, exposure to sCD40L elicited a marked and highly 
significant increase in expression of all three gene products. The most pronounced 
genotype-dependent effect was noted for VCAM-1 followed by MCP-1 and E-selectin 
which were consistently upregulated to a much greater extent in the CC genotype as 
compared to the CT or TT genotype endothelial cells. These pro-inflammatory molecules 
are markers of endothelial dysfunction and their role in macrophage activation and 
leukocyte adhesion in human blood vessels is indisputable (reviewed by Smitzko et al., 
2003; Zhang, 2008). MCP-1 deficient mice on an atherosclerotic background have lower 
levels of aortic lipid deposition despite long-term exposure to a high-fat diet (Brown et al., 
2001) while in VCAM-1 deficient mice the development of atherosclerotic lesions is 
impaired (Cybulsky et al., 2001). Therefore, a CD40-mediated increased expression of 
these gene products would in particular incline the CC genotype cells towards endothelial 
dysfunction.  
The results indicate that increased CD40 abundance on the cell surface corresponds to 
enhanced CD40-mediated downstream signaling to the nucleus, which would induce a 
pro-inflammatory phenotype in the CC genotype endothelial cells (Iezzi et al., 2009). 
Such an amplification of the strength of CD40-CD40L interactions due to constitutive or 
stimulus-dependent differences in CD40 expression has previously been reported by Iezzi 
et al., 2009. Moreover, CD40 belongs to the TNFR superfamily which mediates the 
biological activity of TNF-α (Vandanabeelee et al., 1995). Genetic variations in these 
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receptors are common with a number of SNPs present in the promotor region of these 
genes that significantly affect gene expression (Kim et al., 2005), and which are linked to 
immune-regulatory diseases such as SLE or RA.  
Furthermore, our results also depict a preferential binding of monocytes to endothelial 
cells with the CC genotype. Monocyte adhesion to the endothelial cell surface is 
facilitated by adhesion molecules such as VCAM-1 (Luscinskas et al., 1996). VCAM-1 
expression at mRNA and protein levels was upregulated by sCD40L to a greater extent in 
CC as compared to CT or TT genotype endothelial cells; therefore the functional 
implication of these differences was investigated in an adhesion assay. Monocyte 
adhesion was halved in CT and TT genotype endothelial cells indicating that 
homozygosity of the C allele is required for an enhanced response of these cells to 
sCD40L stimulation. Collectively, CC genotype cells presented a more pro-inflammatory 
phenotype sCD40L stimulation than the CT or TT genotype cells, which both responded 
in a comparable manner. Moreover, these results provide first functional data explaining 
the association of the C allele with inflammatory diseases such as atherosclerosis( Ma et 
al., 2013; Tian et al., 2010; Yun et al., 2014). 
The aforementioned results provide evidence of a -1C/T SNP-dependent effect on 
sCD40L-induced endothelial cell activation. However, under resting conditions CD40 
abundance on the cell surface is maintained at low levels for preservation of a quiescent 
endothelial cell phenotype. Constitutive CD40 expression, which is largely restricted to 
venous and capillary endothelial cells, is affected by micro-environmental factors like the 
presence of inadequate cyclic stretch or pro-inflammatory cell traffic in and out of the 
vessel wall (Korff et al., 2007; Wagner et al., 2011). Moreover, atherosclerotic plaques 
are abundant in pro-inflammatory cytokines like TNF-α and IFN-γ, which are powerful 
stimulators of CD40 expression in vivo (Schoenbeck and Libby, 2001) and in vitro (Kresz 
et al., 1999; Nguyen et al., 2009; Wagner et al., 2002). Furthermore, in inflammation 
endothelial cells are acted upon by sCD40L released from activated platelets, which are 
estimated to contribute to 95% of the sCD40L released into the circulation, in the 
presence of cytokines (Henn et al., 1998 and 2001). Consequently, a combination of pro-
inflammatory mediators which act synergistically is a more suitable mimic of 
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inflammation as opposed to single cytokines, which are commonly used to simulate this 
condition (Franscini et al., 2004). Hence, we next investigated if endothelial cell 
reactivity to cytokine-priming followed by exposure to sCD40L was affected by the  
-1C/T SNP of the CD40 gene. Independent of the genotype, endothelial cells responded 
to cytokine priming plus sCD40L stimulation by significantly upregulating both CD40 
mRNA and protein levels, namely on the cell surface. While the relative increase in 
CD40 abundance was similar in all genotypes, absolute CD40 levels were highest in CC 
genotype endothelial cells both at rest and following cytokine plus sCD40L exposure. We 
were curious if these cells would protect themselves from adopting a pro-inflammatory 
phenotype by reduced reactivity to stimulation, however this was not the case as 
evidenced by the comparable relative rise in CD40 protein in all genotypes following 
stimulation.  
Expression of the selected pro-inflammatory marker genes was also significantly 
upregulated under these conditions, namely that of MCP-1 and E-selectin genes in the CC 
genotype endothelial cells. Regarding VCAM-1, significant differences were not 
observed among the different genotypes; however, as observed in endothelial cells 
exposed to sCD40L alone, maximum upregulation of all marker genes occurred in the CC 
genotype cells. 
These observations suggest that all three genotype have a comparable capacity to 
upregulate CD40 protein under strong pro-inflammatory conditions and the relatively 
greater downstream signaling to the nucleus in CC genotype cells is due to a more 
pronounced cytokine-priming of CD40 expression hence leading to greater abundance of 
CD40. 
It was interesting to note that the presence of one T allele (CT genotype) is sufficient to 
decrease CD40 protein abundance and consequently downstream signaling to the nucleus. 
Presence of the second T allele (TT genotype) mostly had no additional effect on 
downstream signaling despite causing a further decrease in CD40 abundance, suggesting 
that beyond a certain threshold a further decline in the amount of CD40 on the 
endothelial cell surface does not have a measurable impact. Hence sensitivity of the CT 
and TT genotype endothelial cells to stimulation by sCD40L is comparable. This may be 
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due to differential adaptor molecule recruitment by the different genotypes of the -1C/T 
SNP of the CD40 gene. As mentioned before, (section 2.2.3) CD40 mainly signals 
through TRAFs. Whether the TRAFs activate or inhibit downstream signaling depends 
on the cell type and TRAF molecule involved. For instance, in B cells TRAF-3 appears to 
negatively regulate NF-kB, while an opposite effect has been observed in epithelial cells 
using a TRAF3 overexpression system (Propst et al., 2002; Urbich et al., 2001). TRAF-6 
is particularly important in CD40-mediated signaling and is required for the CD40-
mediated activation of important signaling pathways like Akt and p38 in epithelial cells 
(Davies et al., 2005). Therefore, it is plausible that a different TRAF is recruited post-
ligation in CT and TT genotype cells On the whole, these findings suggest that 
homozygosity for the C allele of the -1C/T SNP is required for genetic inclination 
towards a pro-inflammatory endothelial cell phenotype. However, this conclusion may 
not necessarily be applicable to other CD40 expressing cell types. 
Endothelial cell activation promoted by increased adhesion molecule expression is not 
only induced by CD40L but also by the cytokines employed to upregulate CD40 
expression (Landsberger et al., 2007). To investigate if the -1C/T SNP has a general 
influence on endothelial cells under pro-inflammatory conditions; genotype-stratified 
cells were analyzed for differences in pro-inflammatory marker gene expression in the 
absence of CD40L.  
Cytokine exposure induced a similar shift in phenotype as described in the previous two 
sections, with maximum upregulation of CD40 abundance and expression of pro-
inflammatory marker genes in the CC genotype endothelial cells. Changes in gene 
expression were significantly more pronounced than those in non-stimulated cells but less 
than in CC genotype endothelial cells exposed to cytokine priming plus sCD40L 
stimulation (cf. table 12) which could be expected because exposure to the ligand is 
known to amplify the response of endothelial cells to pro-inflammatory cytokines 
(Kotowicz et al., 2010). Since studies regarding the impact of the -1C/T SNP have mostly 
focused on CD40 expression in other cell types and not on CD40-signaling mediated 
susceptibility to atherosclerosis, there is essentially no literature on this subject. However, 
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our results match findings of increased CD40 protein abundance on B lymphocytes from 
CC genotype individuals’ pre and post stimulation with IFN-γ (Tian et al., 2010).  
The impact of the -1C/T SNP on the endothelial cell shift from a quiescent to a pro-
inflammatory phenotype even in the absence of CD40L is noteworthy also because it 
suggests a critical role for this SNP (and of CD40) in a more general pro-inflammatory 
context. This is the first study to functionally investigate the consequences of the -1C/T 
SNP of the CD40 gene on endothelial cell signaling so far. Therefore, it is difficult to 
draw a conclusion as to why the SNP would facilitate such a more general pro-
inflammatory phenotype. One possibility is that the SNP exists in linkage disequilibrium 
(LD) with other SNPs that affect pro-inflammatory endothelial cell responses and thus 
contribute to the observed phenotype. However, this statement is purely speculative and a 
LD of the -1C/T SNP of the CD40 gene with genes in pathways affecting responses to 
pro-inflammatory cytokine is not known except the T/G SNP in intron 2 of the CD40 
gene (Rs4810485) which is in near perfect LD with the -1C/T SNP and associated with, 
e.g. rheumatoid arthritis (Raychaudhri et al., 2009). But since this SNP also exists in the 
CD40 gene, it does not provide a suitable biological explanation for our observation.  
6.4 The C allele of the -1C/T SNP of the CD40 gene is associated with increased 
susceptibility to CHD 
CD40-CD40L interactions are consistently implicated in the pathogenesis of 
atherosclerosis in animal experimental studies, namely in mice (Bruemmer et al., 2001; 
Hakkinen et al., 2000), and downstream signaling in particular in macrophages and 
possibly also in vascular smooth muscle cells (Stojakovic et al., 2007) promotes plaque 
instability (Shoenbeck and Libby, 2001). These interactions play a particularly significant 
role in endothelial dysfunction in inducing pro-inflammatory cytokines, chemokine and 
adhesion molecule expression in endothelial cells (Henn et al., 1998; Pluvinet et al., 
2008). Since downstream CD40 signaling in these cells in the arterial vessel wall 
promotes a pro-atherogenic phenotype, it is highly likely that genetic variations in this 
co-stimulatory receptor-ligand dyad would have an impact on the individual 
susceptibility to atherosclerosis and consequently CHD. Indeed, the CD40 locus is a 
confirmed risk factor for RA; a condition which itself is a risk factor for atherosclerosis 
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and hence CHD (Raychaudhuri et al., 2008). Moreover, CHD and RA seem to have an 
overlapping risk gene profile and there are striking similarities in the pathogenesis, 
namely in the nature of the chronic inflammatory response in the joint or blood vessel, of 
both diseases. 
However, the CD40 gene locus is not included in the 33 loci that have been identified by 
GWAS as confirmed CHD risk factors (Peden and Farrall, 2011). Apart from these 33 
loci, many others have been identified in multiple studies to be nominally significant. It is 
also possible that some genuine disease-related loci are not detected because their 
contribution is too small to cross the stringent threshold of GWAS (must undercut a 
probability value of 5x10
-8
) so that large meta-analyses are required for their detection 
(DiPetrillo et al., 2005). LD, the non-random allelic association of different loci, adds 
another layer of complexity to genetic inheritance. Due to LD, it is possible that the loci 
detected in GWAS are the not the disease-causing ones, but are present because of their 
linked inheritance with the true causative variant resulting in a false positive association 
(Platt, 2010). 
In the light of the importance of CD40-CD40L interactions for inflammation, the -1C/T 
SNP of the CD40 gene has been studied in relation with diseases associated with 
increased inflammation. Thus, the C allele has been linked to acute coronary syndrome 
(ACS) via enhanced CD40 protein expression on platelets and mononuclear cells. No 
association has been reported with stable angina, indicating a direct link of the C allele 
with instability of atheromatous plaques instead of long-term atherosclerosis 
development (Yan et al., 2010; Tian et al., 2010).  
Our experimental results show increased CD40 expression and signaling in CC genotype 
endothelial cells. This allele is also implicated in autoimmune conditions like Graves’ 
disease (Jacobson et al., 2005; Tomer et al., 2002) and Crohn’s disease (Blanco-Kelly, 
2010). Therefore, we compared the distribution of this SNP in a case-control population 
composed of CHD patients and non-diseased controls. The frequency of the C allele was 
significantly higher in the CHD cohort compared to non-diseased controls, and its 
presence conferred a 1.4-fold increased odds of developing CHD compared to the T allele 
which was protective. Subgroup analysis using a recessive model also showed that the TT 
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genotype is associated with reduced risk for CHD (cf. table 13). This observation is in 
line with a meta-analysis pooling results from seven case-control studies investigating 
this SNP with susceptibility to atherosclerosis in a Chinese population, which found a 
significant effect of the C allele under a dominant model. Further sub-group analysis 
showed the C allele to be a risk allele for CHD and ACS under all genetic models (Yun et 
al., 2014).  
Interestingly, the T allele which must be considered protective factor in terms of CHD 
risk, is associated with increased risk of non-Hodgkin’s lymphoma (Skibola et al., 2008; 
Nieters et al., 2011), breast cancer (Shuang et al., 2011), multiple sclerosis (Field et al., 
2011) and chronic hepatitis B viral infection (Zhou et al., 2015). The opposite genetic 
association of the -1C/T SNP of the CD40 gene where the C allele is a risk for 
autoimmune and inflammatory diseases, but provides protection against cancerous and 
infective conditions is intriguing. These findings can be interpreted in view of the 
association of the C allele with increased CD40 protein expression in all cell types 
reported so far (for details please refer to section 5.2). Since CD40 downstream signaling 
rather augments exaggerated immune-regulatory processes, enhanced expression and 
activity would be harmful in a context where inflammation already exists, for instance in 
CHD or RA. However, a reduction may impede B and Th2 cell interactions and hamper 
the adaptive immune system in launching a powerful offensive attack against infectious 
microbes or cancerous cells. In this way, the C allele could be protective for cancer and 
infectious diseases but a risk for autoimmune and inflammatory diseases. In fact, 
considering that this allele is ancestral and dominant in every human population analyzed, 
it would make evolutionary sense for its presence to also confer some advantage to its 
carriers. 
6.5 The -1C/T SNP of the CD40 gene and its effect on circulating soluble CD40 
The association of the -1C/T SNP with autoimmune and inflammatory diseases is widely 
considered to be a consequence of altered CD40 protein expression in various cell types 
due to disruption of the Kozak sequence. However, it is possible that this SNP also 
affects other processes such as control of CD40 downstream signaling through soluble 
CD40 (sCD40) release which may act as a decoy receptor for soluble CD40L. 
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Receptors belonging to the TNF superfamily can exist in membrane-bound or soluble 
forms. The soluble forms (sTNFR) are generated by proteolytic cleavage via the TNF-α 
converting enzyme (TACE) and retain ligand binding capacity, thereby enabling natural 
inhibition of TNF-α signaling through receptor sequestration (Glossop et al., 2005; 
Kohno et al., 1990). They have clinical relevance and are elevated in inflammatory 
conditions like RA (Cope et al., 1992; Steiner et al., 1995). Furthermore, sTNFRII is 
known to be influenced by at least one SNP in RA, indicating genetic regulation (Glossop 
et al., 2005).  
CD40 is a TNFRII and even though sCD40 is known to exist, yet it has not been 
characterized to the same extent as other such molecules. In addition to cleavage of 
plasma membrane-bound CD40 through TACE, sCD40 can also be the product of 
alternative splicing (Tone et al., 2001; Eshel et al., 2008). However, independent of its 
source, current literature suggests an inhibitory role for sCD40 in the immune response 
which is evidenced by its ability to reduce immunoglobulin production by B-lymphocytes 
(Van Kooten et al., 1994; reviewed by Chatzigeorgiou et al., 2009). 
We show here for the first time that human endothelial cells express a transcript that can 
encode sCD40, which indicates their ability to generate sCD40. This transcript, referred 
to as CD40-∆6, was significantly upregulated after exposure to TNF and IFN or a 
combination of these cytokines plus soluble CD40L. However, its upregulation was 
independent of the -1C/T SNP genotype. Furthermore, sCD40 protein was detected in 
endothelial cell supernatants, and this was increased after exposure to sCD40L. These 
results correspond to previous publications reporting the presence of sCD40 in cell 
culture supernatants of human epithelial cells (Eshel et al., 2008) and B lymphocytes 
(Tone et al., 2001).  
In patients with CHD, we observed sCD40 levels exceeding 2300 pg/ml. Interestingly, in 
this  cohort the serum level of sCD40 seemed to correlate with the genotype of the -1C/T 
SNP of the CD40 gene. This was highest in the CC genotype and lowest in the TT 
genotype individuals. Thus, our results are at variance with a recent report by Chen et al. 
(2015) who observed increased sCD40 serum levels in TT genotype individuals in a SLE 
patient cohort. Certainly, it is possible that the serum level of sCD40 is variable and 
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depends on the type of disease. Since sCD40 can be generated by cleavage of the 
membrane-bound receptor, it is possible that it is not functionally relevant but exists in 
higher amounts in the serum from CC genotype individuals simply because of enhanced 
shedding. However, putatively sCD40 acts as a natural inhibitor of CD40L-induced 
signaling by providing an alternative receptor which can bind to CD40L but cannot 
propagate the signal. Therefore, it is also possible that the elevated sCD40 serum levels in 
the CC genotype individuals with CHD is a form of compensation to protect the 
endothelial cells from the deleterious effects of an increased sensitivity towards CD40L 
because of an increased abundance of the receptor on the cell surface. It would be 
intriguing to determine if the effect of the -1C/T SNP on sCD40 levels is specific for 
CHD patients or if it also affects age-matched healthy controls. To determine this, sample 
analysis of sCD40 in control serum is currently underway. 
      6.6 The -1C/T SNP of the CD40 gene and its association with rheumatic diseases 
The -1C/T SNP of the CD40 gene is associated with enhancement of inflammation, 
therefore we have also analyzed whether it is associated also with rheumatic diseases 
such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA).  
In comparison to PsA, RA has been studied in greater detail. CD40-CD40L interactions 
are implicated in RA as evidenced by the association of CD40L-expressing Th1 cells 
with a more active form of the condition (Liu et al., 2001). Moreover, according to our 
data it is strongly associated with increased cardiovascular mortality due to 
atherosclerosis hence CHD. 
There is a significant role for genetic inheritance in the susceptibility to RA, made 
evident by twin and family-based epidemiological studies. The etiology of RA has not 
been completely elucidated but gene-gene and gene-environment hypotheses are widely 
accepted to be critical factors (Kallberg et al., 2007). Family history is a reliable predictor 
for RA incidence (Smolik et al., 2013) while disease probability in monozygotic twins is 
15% compared to 3.5% in dizygotic twins (Silman et al., 1993). Taken together, the 
genetic component of RA risk is estimated to be as high as 60% with a significant 
contribution from the locus of the human leukocyte antigen gene (Bax et al., 2011; 
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Macgregor et al., 2000). Recently, a meta-analysis of three GWAS with a total of 3,393 
cases and 12,462 controls confirmed CD40 as a risk locus for RA in a European 
population (Raychaudhri et al., 2009). 
Considering that both RA and CHD are inflammatory, it was expected that the C allele 
frequency would be similar. As predicted, the MAF in both disease cohorts was 
comparable. However, in the case of RA, the C allele was not significantly associated 
with increased odds of disease development, which is likely because of the comparatively 
small sample size of the RA cohort. Similarly, a nominal but significant association of the 
C allele with RA has been reported in a Spanish cohort (Garcia-Bermudez et al., 2012). 
Furthermore, we analyzed distribution of the -1C/T SNP of the CD40 gene in patients 
with PsA which also is a chronic episodic disease of the joints. While inflammation is the 
hallmark of both types of arthritis analyzed, there are still considerable differences in 
their pathologies and damage pattern. For instance, RA is limited primarily to the 
phalangeal joints of the hands and feet while PsA is more heterogeneous and also 
involves skin lesions and enthesis sites (reviewed by Feale and Veeron, 2015). 
Since this study and the sample collection are ongoing, the sample numbers are not high 
enough to make finite statements. Nevertheless, it is interesting to note the stark 
differences in the distribution of the -1C/T SNP in the RA and PsA cohorts (cf. table 14). 
The PsA cohort has the highest distribution of the C allele (80.8%) and CC genotype 
(63.3%) among all sample sets analyzed thus far. Using umbilical cords as a control 
population, we found a significant association of the C allele with PsA but not RA. These 
results may be interpreted in view of the differential inflammation in RA and PsA. While 
RA is inflammatory, there is greater representation of Th17 cells in PsA (Yeremenko et 
al., 2001). Consequently, the systemic inflammatory response in PsA is considerably 
more enhanced than in RA, with PsA synovial tissue biopsies exhibit greater vascular 
tissue infiltration (Fraser et al., 2001). Furthermore, PsA is thought to be triggered in 
genetically susceptible individuals, in whom the immune system is disrupted, leading to 
joint and skin inflammation (Fitzgerald and Winchester, 2009). Therefore, it is tempting 
to speculate that the C allele significantly contributes to the inflammatory response and is 
thus over-represented particularly in the PsA group. These preliminary results indicate 
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that the -1C/T SNP of the CD40 gene, either directly or as a tag SNP, could be a strong 
predictor or genetic risk factor particularly for PsA development. Since this is the first 
study to associate the -1C/T SNP of the CD40 gene with two different types of rheumatic 
diseases, we cannot compare our results with those of previous reports. 
6.7 Critical analysis of this thesis 
Our study has certain limitations which should be kept in mind. One main critical point is 
that we considered umbilical vein DNA as a non-diseased control sample set and the 
MAF and genotype frequencies of our patients (CHD, RA and PsA) have been compared 
to that cohort instead of an age-matched control. The reason is the difficulty to obtain 
high numbers of age-matched samples which are free from other confounding 
pathologies, particularly in the case of CHD. Nevertheless, we have currently obtained 76 
age-matched non-diseased samples for CHD patients and the MAF and genotype 
distribution was highly comparable with the umbilical cord set. Further sample collection 
is currently underway. 
Another critical point is that we did not stratify the patient cohorts by traditional risk 
factors such as smoking or dyslipidemia. Therefore, odds ratios have been computed 
without such stratification. However, our results are comparable to other studies 
regarding the -1C/T SNP of the CD40 gene in an inflammatory context and are supported 
by in vitro data from endothelial cells; therefore we make the assumption that the 
association of the CC genotype that we detected for both CHD and PsA is in fact 
clinically relevant.  
Finally, we have focused on the -1C/T SNP of the CD40 gene in the context of CHD and 
RA. This SNP is in strong LD with Rs4810485, which is a confirmed risk factor for RA. 
Therefore, in the context of RA and PsA we cannot be certain that our observation is not 
being confounded by the presence of Rs4810485. However, Rs4810485 has been studied 
in RA but not PsA, therefore our study indicates that the -1C/T SNP is a risk factor for 
PsA as a causative or a tag SNP. 
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6.8 Summary and Perspective 
CD40-CD40L interactions are critical for the development and maintenance of a fully 
functional immune system. They have a profound impact on endothelial cells and 
significantly contribute towards their shift from a quiescent to an activated phenotype. In 
humans, a Kozak consensus sequence polymorphism at the -1 position is associated with 
variations in protein translation through altered binding of the mRNA to the ribosome. 
Presence of the cytosine enables the sequence to be ideal and consequently the C-variant 
is associated with increased CD40 expression. 
The present study provides novel evidence demonstrating an association of the 
homozygous C allele with enhanced endothelial CD40 protein expression and 
subsequently stronger CD40-CD40L signaling. A detailed analysis of the pro-
inflammatory phenotype of the CC genotype endothelial cells indicates that the C-variant 
acts as a gain-of-function allele which could genetically predispose individuals towards 
endothelial dysfunction. Since endothelial dysfunction is an early event in chronic 
inflammatory conditions, alterations in endothelial CD40 abundance, namely on the cell 
surface, would have pathophysiological consequences. Accordingly, a case-control study 
of CHD and two types of inflammatory arthritis was carried out which demonstrated an 
association of the homozygous C allele with significantly increased odds of developing 
CHD and PsA; a particularly inflammatory type of arthritis. Furthermore, the 
homozygous C allele was also significantly associated with high sCD40 levels in patients 
with CHD, which is encoded by a transcript that increased under pro-inflammatory 
conditions in endothelial cells.  
While this study adds to the current knowledge of a genetic predisposition to endothelial 
dysfunction with particular regard to the role played by the -1C/T SNP of the CD40 gene, 
yet it also raises further questions which need to be addressed for a more complete 
understanding. For instance, analysis of CD40 expression in genotype-stratified adult 
endothelial cells from CHD patients would provide information regarding the extent of 
the difference that the C allele makes in a CHD context. Furthermore, comparison of 
sCD40 levels in serum of healthy controls with the data from CHD patients would help in 
understanding if the association that we have observed occurs specifically under 
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inflammatory conditions. For this purpose, sample collection of serum from age-matched 
healthy controls is underway.  
This work also provides intriguing preliminary data exhibiting a strong over-
representation of the C allele and CC genotype in patients with PsA. Currently, we are 
expanding this study to include more samples so that a statistically stronger analysis can 
be made. Further studies performing a comparison of endothelial cell proliferation in 
biopsies from PsA and RA patients with the different genotypes would yield interesting 
functional data regarding the inflammatory and proliferative role of this genetic variation 
in an arthritic context. Additionally, sCD40 measurements in arthritic patients would 
provide further information regarding its role as potential (prognostic) biomarker of 
inflammation. 
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Figure 30: Endothelial cells with the CC genotype of the -1C/T SNP are genetically 
inclined towards endothelial dysfunction through enhanced CD40 protein 
expression. Endothelial cells with the C allele and the homozygous C genotype express 
higher CD40 levels due to an optimal Kozak consensus sequence. Consequently, the 
strength of CD40-CD40L signaling is also higher in cells with the CC genotype. 
Therefore, the CC genotype carriers present a more proinflammatory phenotype 
compared to the T allele carriers, which protects the former from susceptibility towards 
endothelial dysfunction. In a case-control study, the C allele was associated with 
increased odds of developing chronic inflammatory diseases represented by CHD and RA. 
Hence the C allele and particularly the CC genotype of -1C/T CD40 is potentially a risk 
factor for immune dysregulation.  
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